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Abstract
Osteoarthritis (OA) is a heterogeneous and multifactorial degenerative disease characterized
by cartilage degradation in the joint. Available treatment options target symptoms but do not
address the underlying issue of joint tissue degeneration. A better understanding of the
molecular mechanisms maintaining cartilage health is essential for developing novel
therapeutic strategies. Previous studies have shown the nuclear receptor Liver X Receptor
(LXR) to possess protective roles against cartilage breakdown in OA, however the
underlying mechanisms behind this process remain unknown. Since LXR regulates
transcription by forming obligate heterodimers with another nuclear receptor, the Retinoid X
Receptor (RXR), I hypothesized that LXR and RXR regulate cartilage development,
maturation and lipid homeostasis.
The first study of this thesis investigated the effect of LXR activation on chondrocyte
differentiation in order to elucidate the molecular mechanisms behind LXR’s protection
against OA. Three different chondrogenic culture systems were treated with the specific LXR
agonist, GW3965, and it was found that LXR activation suppressed chondrocyte
hypertrophy, in part through the delay of cell-cycle exit and consequent retention of
chondrocyte proliferation.
To further identify the intracellular changes that occur to elicit this suppression in
hypertrophy, I conducted microarray analysis on growth plate chondrocytes treated with
GW3965 in my second study. LXR activation caused differential regulation of various genes
involved in lipid metabolism, including central players mediating cellular cholesterol efflux.
i

These findings demonstrate a potential link between LXR’s role in lipid metabolism and the
differentiation of developing chondrocytes.
Lastly, to gain insight into LXR and RXR’s transcriptional effects in articular chondrocytes, I
conducted microarray analysis on immature murine articular chondrocytes (IMACs) treated
with either a LXR or RXR agonist. Both LXR and RXR activation differentially regulated
cellular lipid metabolism. However, they appear to exert opposing effects on cellular
oxidative stress response and maintenance of extracellular matrix (ECM) homeostasis,
suggesting contrasting roles in OA progression.
Collectively, these data demonstrate that LXR and RXR regulate various cellular
mechanisms involved in metabolic homeostasis of both growth plate and articular
chondrocytes. Deeper understanding of nuclear receptor function in chondrocytes will
contribute to better understanding of the molecular pathways controlling cartilage health and
disease.

Keywords
Liver X Receptor, Retinoid X Receptor, Nuclear receptors, Chondrocyte differentiation,
Osteoarthritis, Transcriptional regulation

ii

Co-Authorship Statement
Chapter 2 is adapted from: Sun MM-G, Beier F (2014) Liver X Receptor activation delays
chondrocyte hypertrophy during endochondral bone growth. Osteoarthritis Cartilage
22:996–1006. M.M-G.S. performed all experiments and corresponding data analysis, and
contributed to study design and manuscript writing. F.B. contributed to study conception and
design, and edited the manuscript. Both authors participated in the final approval of the
article.
Chapter 3 M.M-G.S. performed all experiments and corresponding data analysis, and
contributed to study design and manuscript writing. F.B. contributed to study conception and
design, and edited the manuscript. Both authors participated in the final approval of the
article. These data are currently in preparation for submission.
Chapter 4 is adapted from: *Ratneswaran A, *Sun MM-G, Dupuis H, Sawyez C, Borradaile
N, Beier F (2017) Nuclear receptors regulate lipid metabolism and oxidative stress markers
in chondrocytes. J Mol Med 95:431–444. *Equal contributions. M.M-G.S., A.R., and H.D.
performed most experiments and corresponding data analysis. A.R. and M.M-G.S.
contributed to manuscript writing. C.S. conducted all lipid mass experiments, and N.B. is a
collaborator on this project and contributed to manuscript editing. F.B. contributed to study
conception and design, and edited the manuscript. All authors participated in the final
approval of the the article.

iii

Acknowledgements
I would like to take this opportunity to express my sincere gratitude to the many individuals
without whom this thesis would not be possible. First and foremost, I have to thank my
supervisor Dr. Frank Beier, who took a chance and accepted me into his lab 7 years ago as a
clueless undergraduate student. I can honestly say this has changed the trajectory of my life.
Since then, you have given me the chance to cultivate my passion for research and helped me
grow both as a scientist and as an individual. You have always given me the freedom and
independence to explore my limits, yet never fail to provide help at moment’s notice – even
while travelling to various corners of the world attending to PI duties! Thank you for your
wisdom and for your unwavering support throughout these years. I am truly blessed to know
you and to be mentored by you, and can only strive to be half the brilliant and compassionate
individual that you are.
A huge thank you goes out to my advisory committee: Dr. Hardy, Dr. Borradaile, and Dr.
Tirona, for all of their invaluable support and feedback over the years. None of my
accomplishments would be possible without their mentorship, collaboration, and guidance.
Thank you all for making my committee meetings such enriching and fun learning
experiences and for all of your advice.
I don’t think I ever truly grasped how lucky I am to be surrounded by such an amazing group
of people, and I continue to marvel at this each day I arrive at the lab. To the current
members of the Beier lab – thank you all for being the best lab family anyone could ask for.
Holly and Dawn, our lab moms, thank you for being our rock and for maintaining the sanity
of the lab. We literally cannot function without you. Dawn, you are such a brilliant scientist
iv

and amazing person, and I am so honored to have had the chance to learn from you. I am still
figuring out how answers can materialize on my bench just moments after I ask a question,
and I will never again see funky road signs and not think of you. Holly, I still can’t believe
that we’ve travelled together since I was scared of you for 2 solid years. Thank you for
saving my life amidst the glaciers of Iceland, and for inspiring me with your compassion and
resilience. Mike, I will forever regard you as the “senior lab member who knows all things”.
Thank you for showing me what great things dedication and hard work can achieve, and for
putting up with all of my questions about science and beyond. Anusha, my fellow lab troll,
your intelligence and accomplishments never cease to amaze me, and I am so grateful for the
many fun memories we’ve shared both in the lab and all over the world. Thank you for
always being there for me – whether it be on missions to obtain food or the treacherous
journeys to Springett. Toy and Dickens are missing you, as am I. Melina, I cannot imagine
the lab without you, as it would be overtaken by gloom without your cheerful presence. Your
constant support and optimism has helped me through some of the toughest times in lab, and
I appreciate you and your friendship more than you know. Kristyn, my fellow office dweller,
thank you for always being there with the lights turned off and a sassy comment at hand.
You’ve helped make some of the worst days a little brighter (not literally). Supi, your
kindness and wisdom inspires me each day, and your bluntness never fails to make me laugh.
Somehow I feel as though I’ve known you for a long time, and I’m so excited to witness all
of the great things you will achieve in the near future (please hire me!). Ayten, the moment I
spilled soda all over your impeccable dining table I knew you would be one of the most
caring individuals I will ever come across. Thanks for all of your advice on science and life,
and for sharing in mouse pedicuring adventures with me. Manu, your infectious laugh is
something we all miss dearly, and I can’t wait until you are back to continue your Friday
v

night dance parties in the lab. Paxton, your brilliance and ability to manage so many things at
once is something I greatly admire, and I know you will be a great physician and impact the
lives of many. Carina, Julia, and Bethia, I’ve only started getting to know you but am already
impressed by your sense of humor and Friday Bone Club drinks of choice. I’m excited to
spend more time with you and learn from you. Last but not least, Erminers, thank you for all
of your help and for always talking back to me and yelling at me. Lab would not be the same
without your witty remarks.
To the current Seguin lab, thank you for being the best neighbors and collaborators. Dr.
Seguin, thank you for all of your support and for being the epitome of someone I aspire to be
and look up to. Same goes for McCann and Jake, your great achievements continue to inspire
me to work hard every day. Thank you for paving the road for us.
I must also thank the many Beier/Seguin lab alumni that has helped me over the years. To
Ryan P and Chantal, thank you for taking me under your wings, teaching me all there is to
know, and tolerating all of my silly mistakes. Katie and Neil, thank you for starting this grad
school journey with me and for challenging me and befriending me. To Jason, the walking
encyclopedia, thank you for acting as my mentor and for your unfailing source of wisdom.
Your advice on science and life has stuck with me to this day, and I still keep a small stack of
jotted notes from our conversations in case of emergencies.
To my “non-lab” friends, Amanda and Alex, words cannot fathom how grateful I am that
science made us friends. Thank you for being there for me through thick and thin. To my
friends from university, the Korean five, thank you for remaining by my side after all this
time and for always cheering me on.

vi

Finally, I want to thank my family for loving me and raising me. To mom and dad, thank you
for all of the sacrifices you have made so we can have a better life in Canada. You have
taught us the value of education and the determination to pursue our dreams. This degree is
as much yours as it is mine. To my wonderful siblings Tina and Sam, thank you for spoiling
me and for always looking after your little sister, no matter how annoying I can be. Lastly, to
Joe, thank you for being by my side and for doing life with me. I would be lost without you
and I can’t wait to embark on the many more adventures that await us on this incredible
journey.

vii

Table of Contents
Abstract ................................................................................................................................ i
Co-Authorship Statement................................................................................................... iii
Acknowledgements ............................................................................................................ iv
Table of Contents ............................................................................................................. viii
List of Figures .................................................................................................................. xiv
List of Appendices ........................................................................................................... xvi
List of Abbreviations ...................................................................................................... xvii
Chapter 1 ............................................................................................................................. 1
1 Literature Review ........................................................................................................... 1
1.1 Skeletal Development ............................................................................................. 1
1.1.1

Intramembranous Ossification .................................................................... 4

1.1.2

Endochondral Ossification .......................................................................... 4

1.1.3

The Growth Plate ........................................................................................ 5

1.1.4

Molecular Regulation of Endochondral Ossification ................................. 8

1.1.5

Hormonal Regulation of Endochondral Ossification .................................. 9

1.1.6

Vascular Invasion and Bone Formation .................................................... 10

1.1.7

Synovial Joint Formation .......................................................................... 11

1.2 Articular Cartilage ................................................................................................ 12
1.2.1

Articular Chondrocytes ............................................................................. 14

1.2.2

Regulation of the Extracellular Matrix ..................................................... 15

1.2.3

Cartilage Degeneration ............................................................................. 16

1.2.4

Lipid Homeostasis in Cartilage Health ..................................................... 17

1.3 Skeletal Diseases ................................................................................................... 21
1.3.1

Skeletal Dysplasia ..................................................................................... 22
viii

1.3.2

Osteoarthritis ............................................................................................. 23
1.3.2.1 Etiology of OA ........................................................................... 23
1.3.2.2 Metabolic OA ............................................................................. 25

1.4 Nuclear Receptors ................................................................................................. 25
1.4.1

Retinoid X Receptor ................................................................................. 26

1.4.2

Liver X Receptor....................................................................................... 27

1.5 Overall Objectives and Hypotheses ...................................................................... 31
1.5.1

LXR in Endochondral Bone Growth ........................................................ 31
1.5.1.1 Objective #1................................................................................ 31
1.5.1.2 Rationale #1 ................................................................................ 32
1.5.1.3 Hypothesis #1 ............................................................................. 32

1.5.2

LXR-Regulated Genes in Embryonic Chondrocytes ................................ 32
1.5.2.1 Objective #2................................................................................ 32
1.5.2.2 Rationale #2 ................................................................................ 32
1.5.2.3 Hypothesis #2 ............................................................................. 33

1.5.3

LXR and RXR in Articular Chondrocytes ................................................ 33
1.5.3.1 Objective #3................................................................................ 33
1.5.3.2 Rationale #3 ................................................................................ 33
1.5.3.3 Hypothesis #3 ............................................................................. 33

1.6 References ............................................................................................................. 34
Chapter 2 ........................................................................................................................... 50
2 Liver X Receptor activation delays chondrocyte hypertrophy during endochondral
bone growth.................................................................................................................. 50
2.1 Abstract ................................................................................................................. 50
2.2 Introduction ........................................................................................................... 51
2.3 Materials and Methods .......................................................................................... 53
ix

2.3.1

Tibia organ culture .................................................................................... 54

2.3.2

Histology ................................................................................................... 54

2.3.3

Immunohistochemistry (IHC) ................................................................... 55

2.3.4

ATDC5 cell culture ................................................................................... 55

2.3.5

Proliferation assays ................................................................................... 56

2.3.6

Micromass culture..................................................................................... 56

2.3.7

Cell staining .............................................................................................. 57

2.3.8

RNA isolation and real-time PCR............................................................. 58

2.3.9

Protein extraction and Western blotting ................................................... 58

2.3.10 Statistical analysis ..................................................................................... 59
2.4 Results ................................................................................................................... 59
2.4.1

LXR activation alters growth plate morphology ex-vivo ......................... 59

2.4.2

The cell cycle exit marker p57 is decreased in GW3965 treated tibiae .... 65

2.4.3

LXR activation results in decreased hypertrophy and increased
proliferation in ATDC5 cells .................................................................... 65

2.4.4

LXR activation delays chondrocyte differentiation in micromass cultures
................................................................................................................... 70

2.4.5

LXR activation down-regulates gene expression of late-stage
chondrogenic markers in micromass cultures ........................................... 70

2.5 Discussion ............................................................................................................. 74
2.6 Acknowledgements ............................................................................................... 82
2.7 Supplementary Figures ......................................................................................... 83
2.8 References ............................................................................................................. 85
Chapter 3 ........................................................................................................................... 89
3 Liver X Receptor activation regulates lipid homeostasis in growth plate chondrocytes
...................................................................................................................................... 89
3.1 Abstract ................................................................................................................. 89
3.2 Introduction ........................................................................................................... 90
x

3.3 Methods................................................................................................................. 93
3.3.1

Animals and materials............................................................................... 93

3.3.2

Primary cell culture ................................................................................... 93

3.3.3

RNA isolation and microarray analyses ................................................... 94

3.3.4

Bioinformatics analyses ............................................................................ 94

3.3.5

Real-time quantitative polymerase chain reaction (RT-qPCR) ................ 95

3.3.6

Immunohistochemistry ............................................................................. 95

3.3.7

Statistical Analysis .................................................................................... 96

3.4 Results ................................................................................................................... 96
3.4.1

Differential gene expression in response to LXR agonism in growth plate
chondrocytes ............................................................................................. 96

3.4.2

LXR activation in growth plate and articular chondrocytes regulate similar
lipid metabolic processes ........................................................................ 102

3.4.3

LXR activation alters LXR protein localization in the growth plate ...... 102

3.4.4

LXR activation alters localization of metabolic targets in the growth plate
................................................................................................................. 105

3.5 Discussion ........................................................................................................... 112
3.6 Acknowledgements ............................................................................................. 114
3.7 Supplementary Tables ......................................................................................... 115
3.8 References ........................................................................................................... 116
Chapter 4 ......................................................................................................................... 120
4 Nuclear receptors regulate lipid metabolism and oxidative stress markers in
chondrocytes .............................................................................................................. 120
4.1 Abstract ............................................................................................................... 120
4.2 Introduction ......................................................................................................... 121
4.3 Methods............................................................................................................... 124
4.3.1

Primary cell culture and isolation ........................................................... 124

4.3.2

RNA extraction, purification and RT-qPCR ........................................... 124
xi

4.3.3

Microarray and data analysis .................................................................. 126

4.3.4

Cellular lipid mass .................................................................................. 126

4.3.5

Animals and Surgery............................................................................... 127

4.3.6

Immunohistochemistry ........................................................................... 128

4.4 Results ................................................................................................................. 128
4.4.1

Global changes in chondrocyte gene expression in response to nuclear
receptor agonists ..................................................................................... 128

4.4.2

Nuclear receptors affect common biological functions in chondrocytes 129

4.4.3

LXR, RXR and PPAR agonism promote changes in genes involved in
ECM homeostasis and chondrocyte metabolism .................................... 137

4.4.4

Increased expression of oxidative stress markers in osteoarthritic cartilage
................................................................................................................. 143

4.4.5

Changes in gene expression correspond with functional changes in
chondrocyte lipid profile ......................................................................... 148

4.5 Discussion ........................................................................................................... 152
4.6 Acknowledgements ............................................................................................. 156
4.7 Supplementary Tables ......................................................................................... 157
4.8 Supplementary Figures ....................................................................................... 160
4.9 References ........................................................................................................... 164
Chapter 5 ......................................................................................................................... 170
5 Discussion .................................................................................................................. 170
5.1 Overview ............................................................................................................. 170
5.2 Contributions and Significance of Findings ....................................................... 174
5.2.1

Contributions to the field of cartilage biology ........................................ 174

5.2.2

Contributions to the field of osteoarthritis .............................................. 175

5.3 Limitations of Research ...................................................................................... 177
5.3.1

Limitations of in vitro models................................................................. 177

5.3.2

Limitations of genome-wide expression analyses .................................. 179
xii

5.4 Future Directions ................................................................................................ 180
5.5 References ........................................................................................................... 183
Appendices...................................................................................................................... 189
Curriculum Vitae ............................................................................................................ 192

xiii

List of Figures
Figure 1.1 Endochondral Ossification ...................................................................................... 3
Figure 1.2 The Growth Plate..................................................................................................... 7
Figure 1.3 Dysregulation of lipid homeostasis in early osteoarthritis .................................... 20
Figure 1.4 Ligand activation of LXR/RXR heterodimer ........................................................ 30
Figure 2.1 Effect of GW3965 on longitudinal bone growth ................................................... 61
Figure 2.2 Histological analyses of GW3965-treated tibia organ cultures ............................. 64
Figure 2.3 Immunohistochemical analyses of p57 protein localization in GW3965-treated
tibiae........................................................................................................................................ 67
Figure 2.4 Effect of GW3965 on chondrocyte proliferation and hypertrophy in ATDC5 cell
culture ..................................................................................................................................... 69
Figure 2.5 Chondrogenic differentiation of micromass cultures with LXR activation .......... 73
Figure 2.6 Analyses of chondrogenic gene expression in micromass cultures with LXR
activation ................................................................................................................................. 78
Figure 3.1 Microarray analyses of differential gene expression in GW3965-treated primary
chondrocytes ........................................................................................................................... 99
Figure 3.2 Real-time validation of differentially expressed genes in GW3965-treated E15
chondrocytes ......................................................................................................................... 101
Figure 3.3 Comparison of differentially expressed genes in GW3965-treated E15 primary
chondrocytes and GW3965-treated IMAC cultures ............................................................. 104
Figure 3.4 Effect of GW3965-treatment on LXR localization in the growth plate .............. 107
Figure 3.5 Effect of LXR activation on Abca1 localization in the growth plate .................. 109

xiv

Figure 3.6 Effect of LXR activation on Srebp1 localization in the growth plate ................. 111
Figure 4.1 Microarray analyses of nuclear receptor agonist effects on chondrocyte gene
expression ............................................................................................................................. 132
Figure 4.2 Comparison of nuclear receptor agonist effects on chondrocyte gene expression
............................................................................................................................................... 134
Figure 4.3 Comparison of nuclear receptor agonist effects on affected KEGG pathways ... 136
Figure 4.4 Effects of nuclear receptor agonist treatments on extracellular matrix gene
expression in chondrocytes ................................................................................................... 139
Figure 4.5 Effects of nuclear receptor agonist treatment on metabolic gene expression in
chondrocytes ......................................................................................................................... 142
Figure 4.6 Effects of nuclear receptor agonist treatment and OA on Txnip expression ....... 145
Figure 4.7 Effects of nuclear receptor agonist treatment on Gsta4 gene expression ............ 147
Figure 4.8 Quantification of cellular lipid mass in nuclear receptor agonist-treated
chondrocytes ......................................................................................................................... 151

xv

List of Appendices
Appendix A: Animal Use Protocol ....................................................................................... 189

xvi

List of Abbreviations
Abca1

ATP-binding cassette sub-family C member-1 gene

Abcg1

ATP-binding cassette sub-family G member-1 gene

Acsl3

Acyl-CoA synthetase

Actb

Beta-actin gene

ADAMTS-4 A disintegrin and metalloproteinase with thrombospondin motifs-4
ADAMTS-5 A disintegrin and metalloproteinase with thrombospondin motifs-5
Agc1

Aggrecan gene

AGE

Advanced glycation end-product

ALP

Alkaline phosphatase

ANOVA

One-way analysis of variance

ATF4

Activating transcription factor-4

Atx

Autotaxin gene

BMP

Bone morphogenetic protein

CCAC

Canadian Council on Animal Care

CD

Campomelic dysplasia

cDNA

Complimentary DNA

CE

Cholesteryl esters

ChIP-Seq

Chromatin immunoprecipitation-sequencing

CI

Confidence interval
xvii

Col2a1

Type II collagen gene

DAB

Diaminobenzidine

DADA

Diisopropylaminedichloroacetate

DCA

Dichloroacetate

ΔΔCT

Delta-delta cycle threshold

DHA

Docosahexaenoic acid

DMEM

Dulbecco’s Modified Eagles Medium

DMM

Destabilization of the medial meniscus

DMSO

Dimethylsulfoxide

E15.5

Embryonic day 15.5

ECM

Extracellular matrix

EPA

Eicosapentaenoic acid

ERR

Estrogen-related receptors

FBS

Fetal bovine serum

FC

Free cholesterol

FXR

Farnesoid X Receptor

GAG

Glycosaminoglycan

Gapdh

Glyceraldehyde-3-phosphate gene

Gdf5

Growth differentiation factor-5 gene

GEO

Gene expression omnibus

xviii

GH

Growth hormone

GHR

Growth hormone receptor

GLUT

Glucose transporter

GO

Gene ontology

Gsta4

Glutathione S-Transferase a-4

GWAS

Genome-wide association studies

HA

Hyaluronic acid

HNE

4-hydroxynonenal

HS

Heparin sulfate

IGF-1

Insulin-like growth factor-1

IHC

Immunohistochemistry

IHH

Indian hedgehog

IL-1b

Interleukin-1b

IMACs

Immature murine articular chondrocytes

ITS

Insulin-transferrin-selenium

KEGG

Kyoto Encyclopedia of genes and genomes

L-Sox5

SRY (sex-determining region)-box 5

LCPUFA

Long-chain polyunsaturated fatty acid

Lpcat3

Lysophosphatidylcholine acyltransferase-3

LXR

Liver X Receptor
xix

LXRE

Liver X Receptor response element

MMP13

Matrix metalloproteinase-13

NF-kB

Nuclear factor k-light-chain-enhancer of activated B cells

OA

Osteoarthritis

OXS/SP7

Osterix

PBS

Phosphate buffered saline

PDC

Pyruvate dehydrogenase complex

PDK

Pyruvate dehydrogenase kinase

PFA

Paraformaldehyde

PL

Phospholipids

PPAR

Peroxisome proliferator-activated receptor

PRG4

Lubricin/Proteoglycan-4

PSA

Puck saline A

Ptc1

Patched 1

PTHrP

Parathyroid hormone related peptide

PVDF

Polyvinylidene fluoride

PXR

Pregnane X Receptor

RA

Rheumatoid arthritis

RAR

Retinoic acid receptor

RIN

RNA integrity number

xx

RORa

RAR-related orphan receptor-a

ROS

Reactive oxygen species

RT-qPCR

Real-time quantitative polymerase chain reaction

RUNX2

Runt-related transcription factor 2

RXR

Retinoid X Receptor

SAPL

Surface-active phospholipid

Scd1

Stearoyl-CoA desaturase

Smo

Smoothened

SNP

Single-nucleotide polymorphism

Sox6

SRY (sex-determining region)-box 6

Sox9

SRY (sex-determining region)-box 9

Srebf1/Srebp1 Sterol regulatory element-binding transcription factor-1 gene
T3

3,5,3’-L-triiodothyronine

TC

Total cholesterol

TG

Triglyceride

Tgfbr2

Transforming growth factor-b receptor 2 gene

TH

Thyroid hormone

TNF-a

Tumor necrosis factor-a

TRa1

Thyroid hormone receptor a-1

TRb1

Thyroid hormone receptor b-1
xxi

TRb2

Thyroid hormone receptor b-2

Txnip

Thioredoxin-interacting protein

VEGF

Vascular endothelial growth factor

Wnt9a

Wnt family protein 9A gene

xxii

1

Chapter 1

1

Literature Review

1.1

Skeletal Development

The skeleton is an organ that possesses tremendous biological importance. Its evident
functions include organ protection, locomotion, and height determination [1, 2].
Evolutionary pressures faced by early terrestrial animals gave rise to an expansive
skeletal endocrine network that maintains mineral ion homeostasis and controls global
energy metabolism [3, 4]. Proper skeletal development is therefore essential, as
abnormalities could result in serious implications in growth disorders, metabolic bone
diseases, and joint pathology [4–6].
Skeletogenesis begins with the aggregation of mesenchymal cells at locations of future
bones, where pattern formation regulates the morphogenesis of skeletal elements [7, 8].
These cells form high-density mesenchymal condensations, and either differentiate into
osteoblasts to directly form bone, or differentiate into chondrocytes to form a cartilage
template of future bones [8, 9]. Cartilage-independent bone formation is referred to as
intramembranous ossification, and takes place in regions of the craniofacial skeleton and
the clavicle [7, 10]. The posterior part of the skull and the appendicular and axial skeleton
are formed through a cartilage intermediate in a process known as endochondral
ossification [7, 11], and is summarized in Fig. 1.1.
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Figure 1.1 Endochondral Ossification. Longitudinal bone growth occurs through the
process of endochondral ossification, which begins with the condensation of
mesenchymal precursor cells. Chondrogenic differentiation is initiated under the control
of SOX9, where chondrocytes then begin to proliferate while producing an extracellular
matrix rich in collagen II and aggrecan. Proliferating chondrocytes eventually undergo
hypertrophy starting from the center of the cartilage anlage, and express cartilage
degrading enzymes while initiating mineralization of the matrix. Invasion of blood
vessels, osteoblasts, and osteoclasts removes the cartilage matrix for the deposition of
bone, forming the primary ossification center. Postnatally, similar differentiation
processes occur at either ends of the bone to form the secondary ossification centers.
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Figure 1.1 Endochondral Ossification
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1.1.1

Intramembranous Ossification

Intramembranous ossification occurs when cells within mesenchymal condensations
undergo differentiation into osteoprogenitor cells, which further proliferate and
differentiate into osteoblasts at osteogenic fronts [12, 13]. Osteoblasts are responsible for
secreting an organic, collagenous extracellular matrix (ECM) to form ossification centers
that subsequently become mineralized through deposition of hydroxyapatite crystals [9,
14]. Three important transcription factors: runt-related transcription factor 2 (RUNX2),
osterix (OXS/SP7), and activating transcription factor-4 (ATF4), govern the
differentiation and maturation process of osteoblasts [12, 14, 15]. Together with
numerous other transcription factors and signaling molecules that modulate cellular
proliferation and osteoblastogenesis, they regulate the intricacies of bone formation.

1.1.2

Endochondral Ossification

Longitudinal bone growth in the body is attributed to the process of endochondral
ossification, in which a cartilage template intermediate is formed and then replaced by
bone specific matrix [16, 17]. During this process, chondrocytes within this cartilage
template undergo various maturation steps [18]. Mesenchymal precursor cells first
condense, then chondrogenic differentiation is initiated under the control of the
transcription factor SRY (sex determining region Y)-box 9 (SOX9) [18, 19]. As these
chondrocytes proliferate, the expression of Sox9 and the induction of its target genes lead
to the production of an extracellular matrix rich in collagen II and aggrecan [18, 20]. This
occurs through the cooperative binding of the “Sox Trio” (Sox9, L-Sox5, and Sox6) to
enhancers of the collagen-II (Col2a1) and aggrecan (Agc1) genes, whereby L-
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SOX5/SOX6 secures and increases SOX9 binding efficiency for optimal activation of
these essential chondrogenic markers [21].
Proliferating chondrocytes eventually withdraw from the cell cycle and undergo
hypertrophy starting from the center of the cartilage anlage [17, 22]. These hypertrophic
chondrocytes express cartilage degrading enzymes and initiate mineralization of the
matrix [18]. Cartilage degradation is accompanied by the invasion of blood vessels,
osteoblasts, and osteoclasts to remove the cartilage matrix for the deposition of bone
matrix, ultimately forming the primary ossification center [17, 18]. Postnatally,
chondrocytes at the two distal ends of the bone undergo a similar differentiation process
to form the secondary ossification centers [23]. The developing cartilage that remains
between the primary and the secondary ossification centers is defined as the growth plate,
consisting of distinct cell layers of resting, proliferative and hypertrophic zones [16, 18].
The growth plate is depicted in Fig. 1.2.

1.1.3

The Growth Plate

The growth plate is a dynamic structure that ultimately allows bones to grow in length.
To do this, chondrocytes within the growth plate undergo a series of morphological and
molecular changes to create an ossification front that pushes apart the growth plates at
either ends of the bone as the bone continues to grow [24]. This process is highly
regulated by a complex system of transcription factors, signaling molecules, and
paracrine and endocrine factors [25, 26]. The growth plate is established by the end of the
first trimester in humans and will persist until the end of the pubertal stage during
adolescence [24, 26].
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Figure 1.2 The Growth Plate. The growth plate is the developing cartilage between the
primary and the secondary ossification centers during endochondral ossification. It is
composed of distinct cell layers of resting, proliferative, and hypertrophic zones. As
growth plate chondrocytes undergo this series of morphological and molecular changes,
an ossification front is created which pushes apart the growth plates at either ends of the
bone as the bone grows.
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Figure 1.2 The Growth Plate
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The zone furthest away from the ossification front is the resting zone, which has a high
ratio of extracellular matrix to cell volume and consists of small, round cells of relatively
quiescent nature [27, 28]. It has been suggested that resting chondrocytes possess stemlike qualities to act as precursors of proliferative chondrocytes, where depletion of resting
chondrocytes’ proliferative capacity has been shown to cause growth plate senescence
[27, 29]. Adjacent to the resting zone, proliferative chondrocytes take up a distinctive
flattened shape and become organized in a columnar fashion along the axis of the bone,
and strongly express Col2a1 in order to synthesize and deposit cartilage-specific matrix
[24, 26]. Eventually proliferative chondrocytes cease proliferating, exit the cell-cycle, and
change their cellular program to differentiate into hypertrophic chondrocytes [26].
Hypertrophic chondrocytes are principal contributors of bone growth due to their marked
cell volume increase, and form the essential interface in the cartilage to bone transition by
expressing collagenases such as matrix metalloproteinase 13 (MMP13) to resorb the
cartilage ECM, vascular endothelial growth factor (VEGF) to attract blood vessels and
osteoclasts, as well as alkaline phosphatase to initiate mineralization of the surrounding
matrix [28, 30, 31]. Concomitantly, hypertrophic chondrocytes also signal to adjacent
perichondral cells to become osteoblasts, forming the bone collar [32].

1.1.4

Molecular Regulation of Endochondral Ossification

Upon exiting the cell-cycle and prior to becoming hypertrophic, chondrocytes exist in a
pre-hypertrophic/early hypertrophic state and expresses the signaling molecule Indian
hedgehog (IHH) [26, 32]. In addition to its roles in coordinating osteoblast
differentiation, IHH also induces parathyroid hormone related peptide (PTHrP)
expression in the perichondral and proximal chondrocytes [26, 32–34]. The PTHrP/IHH
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signaling axis controls the transition from proliferative to pre-hypertrophy through a
negative feedback system [35]. PTHrP secreted at the ends of long bones act on adjacent
proliferating chondrocytes to maintain their proliferation, while chondrocytes further
away experience diminished stimulation by PTHrP and therefore exit the cell cycle to
become pre-hypertrophic and produce IHH, which in turn induces PTHrP expression in
the ends of the bones [34, 35]. Without proper PTHrP/IHH signaling, chondrocyte
proliferation and hypertrophy is greatly impaired, leading to skeletal malformation [33,
34, 36].

1.1.5

Hormonal Regulation of Endochondral Ossification

The process of endochondral ossification is tightly regulated by a myriad of endocrine
factors, which exert their effect by acting directly on the growth plate or by modulating
other endocrine networks [37]. Among these, several have been extensively characterized
due to the severe skeletal impairment that results with perturbation of its signaling
pathway. Growth hormone (GH) has long been known to have important implications in
longitudinal bone growth, where GH deficiency and/or insensitivity can severely impair
bone growth [38]. GH mainly exerts its effects on skeletal growth through the insulin-like
growth factor-1 (IGF-1), where administration of IGF-1 is able to partially compensate
growth hormone receptor (GHR) deficiency and rescue the resulting dwarfism in both
mice and humans [39, 40]. However, it has been shown that GH can also act directly on
the growth plate to stimulate proliferation of resting chondrocytes as a mechanism for
bone growth [41].
Thyroid hormone (TH) is another important systemic regulator of bone growth. The
active form of thyroid hormone, 3,5,3’-L-triiodothyronine (T3), binds to thyroid hormone
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receptors (TRa1, TRb1, TRb2) expressed in resting and proliferating chondrocytes of the
growth plate with high affinity [42]. The most prominent effect of T3 on growth plate
chondrocytes is its inhibition of cell proliferation and promotion of chondrocyte
hypertrophy and associated cartilage matrix mineralization [42–44]. The dependence of
terminal chondrocyte hypertrophy on thyroid hormone suggests thyroid hormone
regulates linear growth through alteration of the IHH/PTHrP negative feedback loop,
whereby thyrotoxicity prevents PTHrP signaling to promote chondrocyte hypertrophy
and hypothyroidism increases PTHrP expression to inhibit chondrocyte hypertrophy [45].
Furthermore, T3 has also been reported to negatively regulate the expression of heparin
sulfate (HS) proteoglycans [46], while inducing collagen-degrading enzymes in the
growth plate matrix [47, 48]. Taken together, thyroid hormone is an important regulator
of longitudinal bone growth through its potent effects on both chondrocyte differentiation
and cartilage matrix remodeling.

1.1.6

Vascular Invasion and Bone Formation

Formation of the primary ossification center begins with development of the bone collar
around the midshaft of the cartilage anlage, followed by mineralization of the
surrounding matrix and vascular invasion [49, 50]. The replacement of growth plate
cartilage by bone occurs at the chondro-osseous junction, where hypertrophic
chondrocytes are replaced upon reaching terminal differentiation. This occurs either
through apoptotic mechanisms or through transdifferentiation of hypertrophic
chondrocytes down the osteoblastic lineage to contribute to the osteogenic pool [51–53].
The coupling of cartilage resorption to bone formation is in part dependent on VEGF-
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mediated vascular invasion, through which osteoblasts and osteoclasts are recruited to
facilitate this transition [54, 55].
Secondary ossification center formation differs from that of the primary ossification
center through bypassing bone collar formation and cartilage mineralization [50]. Instead,
vascularized cartilage canals run through the uncalcified cartilage to supply a path for
osteogenic cells [56]. Canal formation is preceded by MMP and macrophage activity that
cleave and resorb areas of the cartilaginous matrix, and is coupled with both the death of
surrounding resting chondrocytes as well as their release into the canal cavity, potentially
entering an osteogenic lineage [56]. As these events occur in the middle of the epiphyses,
secondary ossification is therefore sometimes referred to as epiphyseal ossification [50].

1.1.7

Synovial Joint Formation

Skeletal elements are linked together through joints in order to form a skeleton and to
impart their function. Synovial joints are comprised of a collection of tissues enclosed
within a fluid-filled fibrous capsule, and include the articular cartilage, bone, ligament,
and synovium [57]. Being the most common and mobile joint type within the body, the
synovial joint is subject to highly prevalent degenerative diseases that can greatly impair
mobility and quality of life [9, 57].
Synovial joints formation occurs in tandem with the development of the skeletal elements
they articulate [9, 58]. The first process that occurs is known as joint specification,
whereby a subset of skeletal progenitor cells is directed down the articular fate [59]. In
addition to expressing Sox5/6/9, these articular progenitor cells also uniquely express
growth differentiation factor 5 (Gdf5), Wnt family protein 9A (Wnt9a), transforming
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growth factor-beta receptor 2 (Tgfbr2), and autotaxin (Atx).

These cells form the

interzones at presumptive joint sites [60–64]. Once an interzone has been specified, joint
morphogenesis takes place and is characterized by joint cavitation, the development of
non-cartilaginous structures of the joint, as well as formation and maintenance of the
articular cartilage [9, 57]. Recent studies suggest the latter to stem from a small
population of distal proliferating chondrocytes that resist hypertrophic differentiation to
become articular chondrocytes [65]. This occurs in part due to their expression of the
bone morphogenetic protein (BMP) antagonist Noggin, insulating them from exposure to
BMP signaling and preventing their differentiation into transient growth plate cartilage
[65].

1.2

Articular Cartilage

As previously discussed, the growth plate cartilage is a transient structure composed of
chondrocytes undergoing highly dynamic maturation processes. In contrast, the articular
cartilage is a stable and permanent structure that provides smooth articulation and even
load distribution across the joint surface [64, 66, 67]. Due to its aneural and avascular
composition and low cellular density, the articular cartilage possesses low regenerative
capabilities [68, 69]. The articular cartilage predominantly consists of ECM, which is
composed of an extensive network of collagen II, IX, and XI to provide tensile strength,
and proteoglycans such as aggrecan to exhibit compressive resistance [69]. Proteoglycans
are bound to hyaluronic acid (HA) polymers through link proteins, and are associated
with large numbers of glycosaminoglycans (GAGs) that allow hydration and swelling of
the tissue to withstand repetitive compressive loading [70].
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The zonation organization of articular cartilage divides the tissue into the superficial,
intermediate, and deep zones [6, 70]. The superficial zone consists of chondrocytes and
collagen fibrils oriented in parallel to the cartilage surface, allowing it to possess the
highest tensile strength of the whole tissue [6, 70]. These superficial chondrocytes, as
well as some upper intermediate chondrocytes, also secrete lubricin/proteoglycan-4
(PRG4), a unique glycoprotein that plays an important role in lubricating the joint surface
to allow for near frictionless movement [70, 71]. The intermediate zone immediately
below contains lower cell density and more randomly organized collagen fibrils in order
to allow transition into the deep zone [49, 70]. Cellular density and collagen content is at
the lowest in the deep zone, which is situated between the intermediate zone and a
calcified cartilage layer [49, 70]. This calcified cartilage forms an interface with the deep
zone called the tidemark, and acts to prevent vascular invasion into the overlying articular
cartilage, anchor the articular cartilage to the subchondral bone, and allow transmission
of forces across the joint [49, 70, 72].
The articular cartilage ECM can also be distinguished regionally with respect to distance
from the chondrocyte. The matrix immediately surrounding chondrocytes is known as the
pericellular matrix, and contains concentrated amounts of collagen VI, decorin, and
aggrecan [69, 70]. Despite its low collagen content, the pericellular matrix contains
collagen VI that interacts with HA and decorin to maintain chondrocyte attachment [69,
70]. The interterritorial matrix is the matrix most remote from chondrocytes, and is
believed to contain degradation products of aggrecan in addition to abundant collagen
[69, 70].
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1.2.1

Articular Chondrocytes

Chondrocytes are the unique resident cell type found within cartilage and are essential for
cartilage formation and function [73]. In human articular cartilage, chondrocytes make up
around 2% of the total cartilage volume, and are located within matrix cavities known as
lacunae [69, 73, 74]. Despite such a low cellular volume density, articular chondrocytes
are absolutely essential for the formation of the surrounding ECM and for overall
maintenance of tissue homeostasis [69].
The avascularity of the articular cartilage means that access to nutrition and metabolites
depends on diffusion from the synovial fluid or the underlying subchondral bone, which
inevitably results in gradient formation [75, 76]. Chondrocytes exist under conditions of
oxygen tension ranging from 10% at the surface to as low as 1% in the deep zone, and
primarily undergo anaerobic glycolysis to meet energy demands [75, 76]. Several glucose
transporters (GLUT), including GLUT1 and GLUT3, mediate facilitated glucose
transport in chondrocytes [77]. While glucose serves as the major energy source in
chondrocytes, lipids are necessary as an alternative source of energy and to serve
essential structural and signaling functions [78]. Lipids are conventionally transported
through blood bound to carrier proteins or as lipoproteins, however there is evidence
suggesting certain lipids to first dissociate from carrier proteins prior to diffusing into the
cartilage [79]. Additionally, proteins responsible for lipid metabolism and biosynthesis
are present in human chondrocytes, indicating lipid content to also stem from de novo
synthesis [78].
Death of articular chondrocytes strongly affects cartilage integrity, and can occur through
apoptosis, necrosis, or oncosis (cell death involving cell swelling and coagulation of the
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cytoplasm) caused by factors such as injury and aging [80]. Similar to various other celltypes, the accumulation of damaged or harmful cytoplasmic materials can compromise
cellular function and survival [81]. Autophagy targets and translocates these
dysfunctional cytoplasmic macromolecules to the lysosome for degradation, and is an
important mechanism protecting against cellular stress and consequent death [82, 83].
Interaction of integrins with ECM components also plays a role in chondrocyte survival,
where cell adhesion and integrin-mediated signals are required for proper chondrocyte
differentiation and development [81, 84]. However, articular chondrocytes do not
normally undergo terminal differentiation or cell death, and atypical changes in this
manner can occur as a result of injuries or stress to contribute to cartilage breakdown
[85].

1.2.2

Regulation of the Extracellular Matrix

The cartilage ECM is a structure that undergoes controlled remodeling much like all
tissues within the body [86]. However, under normal conditions the cartilage ECM
remains relatively stable and experiences low turnover due to low metabolic activity of
chondrocytes [87]. There is minimal chondrocyte division and no extensive production of
ECM components is needed, since the half-life of collagen II is more than 100 years
while the maximal half-life of aggrecan is around 25 years [69, 87]. Despite a seemingly
low activity profile, the adult articular cartilage responds to mechanical stimulation and
requires an optimal level to maintain viability [87, 88]. Normal physiological loading of
the joint, such as dynamic compressive loading, supports ECM synthetic activity,
whereas abnormal, excessive, or absence of loading can result in disruptions of ECM
homeostasis [87–89]. Additionally, changes in the stiffness of the ECM can alter load
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distribution and force transmission to elicit changes in chondrocyte response and
metabolism [90–92]. Both aging and mechanical stress can cause matrix stiffening due to
cross-linking of collagen in the presence of advanced glycation end-product (AGE)
accumulation, causing an increase in catabolic factors and a decrease in synthesis of
ECM components [93]. More recently, mechanotransduction in chondrocytes has been
found to occur largely through the primary cilia, which are aligned with the ECM to act
as a sensory organ and process mechanical stimulation and osmotic loading [88]. The
primary cilia therefore regulate various mechanosensitive intracellular pathways,
including IHH signaling, whose receptor Patched 1 (Ptc1) and its target Smoothened
(Smo) are both localized to the cilia [94, 95].

1.2.3

Cartilage Degeneration

How chondrocytes maintain their ECM under healthy conditions is still largely
unexplored, and most of what we currently know regarding matrix remodeling stems
from examining the articular cartilage under diseased states. Cartilage degeneration is
characterized by an imbalance of ECM homeostasis where catabolic activities surpass
anabolic activities, and an up-regulation of cartilage degrading enzyme production leads
to cartilage destruction [96–98]. Among the most well-characterized cartilage degrading
enzymes are MMP-13, a zinc-dependent endopeptidase enzyme that can degrade all
components of the ECM, as well as a disintegrin and metalloproteinase with
thrombospondin motifs 4 and 5 (ADAMTS-4 and -5), aggrecanases that are principally
responsible for aggrecan breakdown [99, 100].
Studies examining cartilage degeneration in osteoarthritis (OA), one of the most
prevalent degenerative joint diseases, show inflammation to be a key factor in driving
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ECM changes associated with cartilage breakdown [66, 67, 99]. Proinflammatory
cytokines such as interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a) are able to
work synergistically to suppress ECM synthesis and induce expression of matrixdegrading enzymes [101, 102]. This occurs through activation of nuclear factor kappalight-chain-enhancer of activated B cells (NF-kB), a transcription factor that increases the
expression of both cartilage-degrading enzymes and the proinflammatory cytokines that
induce them [99, 103]. As cartilage breakdown products, such as the aggrecan 32-mer
fragment, can also act as endogenous ligands activating the NF-kB signaling pathway,
this creates a positive feedback mechanism of which further perpetuates cartilage
degeneration [104].
Cartilage degeneration can occur in both transient and permanent cartilage, where it is
necessary for the replacement of the growth plate by bone, but only occurs in articular
cartilage under diseased states such as OA. In both transient and permanent cartilage,
abnormal cartilage degradation is linked to atypical differentiation and phenotypic
changes of chondrocytes, where dysregulation of chondrocyte proliferation and
hypertrophy may lead to skeletal deformities and articular cartilage breakdown [85]. As
such, the regulatory mechanisms behind chondrocyte differentiation should be further
elucidated to better understand normal cartilage health.

1.2.4

Lipid Homeostasis in Cartilage Health

Lipids in cartilage are an important source of energy and are known to act as structural
components and signaling molecules [105]. Appropriate lipid content and metabolism are
essential for normal cartilage function, where dysregulation of lipid homeostasis can lead
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to cartilage pathophysiology. Lipids have been shown to accumulate in the superficial
zone of the osteoarthritic cartilage [106], as well as within osteoarthritic chondrocytes
[107]. As reactive oxygen species (ROS) production and oxidative stress is often
associated with osteoarthritis, this can lead to lipid peroxidation and the resulting
MMP13 induction and cleavage of collagen by lipid peroxidation products [108–110], as
summarized in Fig. 1.3. Of all the molecules that constitute the diverse group of lipids,
cholesterol and fatty acids are the most well studied and commonly implicated in
cartilage biology, while less is known about the function of phospholipids in joint health
[105].
Hypercholesterolemia has been consistently associated with OA, and cholesterol
biosynthesis has been found to be up-regulated in osteoarthritic chondrocytes [111–113].
Cholesterol deficiency due to inborn errors of cholesterol synthesis, however, typically
results in several different forms of congenital skeletal dysplasia [114]. Studies altering
the biosynthetic pathway of cholesterol in rats have shown this to be due to the
requirement of cholesterol for proper processing and distribution of IHH, and
subsequently its downstream regulation of chondrocyte proliferation and hypertrophy
within the growth plate [115, 116].
Like cholesterol, long-chain polyunsaturated fatty acids (LCPUFAs) have also been
shown to play important roles in both skeletal development and cartilage health. Omega3 (ω-3) and omega-6 (ω-6) are LCPUFAs that contain an unsaturated carbon at the third
and sixth position from the methyl terminal, respectively [117]. ω-3 and ω-6 fatty acids
are derived from dietary α-linolenic and linoleic acid, and can be further desaturated and
elongated to form ω-6 arachidonic acid, ω-3 eicosapentaenoic acid (EPA) and ω-3
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Figure 1.3 Dysregulation of lipid homeostasis in early osteoarthritis. This schematic
represents the proposed role of dysregulation of lipid homeostasis in osteoarthritis (OA)
onset. In contrast to healthy cartilage (left), lipid accumulation in osteoarthritic cartilage
(right) can lead to lipid peroxidation by reactive oxygen species (ROS), resulting in
cleavage of collagen and subsequent cartilage degradation. This can occur alongside
cellular changes such as hypertrophy and clustering of chondrocytes, further driving
cartilage breakdown.
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Figure 1.3 Dysregulation of lipid homeostasis in early osteoarthritis
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docosahexaenoic acid (DHA) [118]. Despite studies showing administration of ω-3 fatty
acids to exert beneficial effects such as accelerated bone growth, improved bone quality,
and reduced OA pathology, recent studies showing delayed OA pathology as a result of
decreased ω-6 to ω-3 ratio suggest a balance of ω-6 and ω-3 fatty acids to be more
physiologically preferable [117, 119, 120]. However, endogenous conversion of ω-6 to
ω-3 does not occur naturally in mammals, and as a result humans need to resort to dietary
intake to achieve the ideal ratio.
Phospholipids (PL) have been found to be adsorbed to the articular cartilage surface in
the form of a membrane-like sheet, with the hydrophobic hydrocarbon chains oriented
outwards to contribute to cartilage hydrophobicity [121, 122]. Furthermore, PL
concentration have been shown to be increased in the synovial fluid of OA and
rheumatoid arthritis (RA) patients compared to control patients, likely due to destruction
of the cartilage surface and disruption of the phospholipid layer [123]. Together with
their load-bearing capabilities in reducing friction, surface-active phospholipids (SAPLs)
have thus been highly speculated to contribute to boundary lubrication of the joint,
although further studies are necessary to elucidate their exact roles [124].

1.3

Skeletal Diseases

Alterations in the developmental and aging processes of cartilage and bone can contribute
to a variety of skeletal diseases. Specifically, perturbation in the regulation of
chondrocyte differentiation and extracellular matrix homeostasis can manifest in both
growth disorders and degenerative joint diseases, such as skeletal dysplasias and different
types of arthritis [49, 125]. As a large variety of different skeletal diseases are known, I
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will limit my discussion to only those pertaining to dysregulation of cartilage
development, maturation, and maintenance.

1.3.1

Skeletal Dysplasia

Skeletal dysplasias are a heterogeneous group of generalized disorders of bone and/or
cartilage,

and

include

osteochondrodysplasias

and

dysostoses

[126,

127].

Osteochondrodysplasias are disorders associated with abnormalities in the development
of the appendicular or axial skeleton, and can result in short stature or alterations in bone
mineralization and density [126, 127]. Similarly, dysostosis refers to malformation of a
single or group of skeletal element [126].
In humans, loss-of-function mutation in transcription factor SOX9, the master regulator
of chondrogenic differentiation, results in a severe form of dwarfism known as
campomelic dysplasia (CD) [128, 129]. Due to impaired synthesis of the cartilage matrix,
patients with CD are characterized by bowing and angulation of long bones, small
ribcage with decreased number of ribs, defective airway, and smaller skull base [7, 125].
Many of these defects are similar to mutations of collagen II, which results in a spectrum
of chondrodysplasias collectively termed the type II collagenopathies [130, 131].
Symptoms of type II collagenopathies range from severe dwarfism, underossification of
the axial skeleton, and lethality (achondrogenesis type II, hypochondrogenesis), to
normal adult height with early-onset OA (stickler dysplasia, dominant spondylarthropathy) [130]. Similarly, mutations in collagen IX, a minor collagen found in the
cartilage ECM, results in multiple epiphyseal dysplasia characterized by mildly decreased
stature and a spectrum of early-onset osteoarthritic symptoms [132, 133]. Importantly,
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these are just a few examples of the more than 100 different osteochondrodysplasias
known.

1.3.2

Osteoarthritis

Osteoarthritis is the most common type of arthritis and the primary cause of disability in
elderly populations [134, 135]. In fact, it has been estimated worldwide that 10% of men
and 18% of women above 60 years of age report symptomatic OA [136]. Symptoms of
OA encompass a spectrum of conditions that greatly interfere with the quality of life,
including chronic pain and impaired physical function due to instability and buckling [66,
137]. This leads to incurrence of substantial indirect costs, which in addition to direct
health-care costs amount to tremendous socioeconomic burden [138]. A study done in
1997 estimated the cost of OA to be 1-2.5% of the gross national product for countries
such as Canada and the United States, a statistic that is bound to increase with OA
prevalence expected to double by 2020 [139, 140]. In order to mitigate this disease
impact, better understanding of the pathophysiology of OA is needed to develop effective
therapeutic strategies that prevent OA onset and structural progression. This will in turn
facilitate early diagnosis and better disease management to help improve treatment
outcome.

1.3.2.1

Etiology of OA

Osteoarthritis is conventionally classified into two types: primary (idiopathic) and
secondary (attributable to a specific cause) [141]. Although primary OA develops in the
absence of a known cause, it is usually associated with increasing age and rarely occurs
in individuals younger than 40 years of age [142]. Alternatively, secondary OA develops
as a result of an identifiable cause, which can range from joint injuries to hereditary,
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metabolic, inflammatory, or developmental factors [142]. The distinction between
primary and secondary OA is not always clear, and it is likely that many patients with
primary OA have a predisposing cause such as increased genetic susceptibility or
increased mechanical stress [142]. Indeed, certain aspects of OA progression can remain
indistinguishable regardless of etiology of disease.
Several risk factors have been extensively studied in order to modify their disease impact
and to improve and implement interventions. Among them, age is the most commonly
associated risk factor and one of the strongest predictors of OA [143, 144]. This is likely
due to the impact of aging on the function and integrity of all tissues in the joint, as well
as a decrease in repair response leading to further disease progression [143]. The role of
gender has also been highly implicated in OA, where females are associated with higher
risk and prevalence of hand and knee OA [145]. Studies on post-menopausal women
strongly suggest estrogen deficiency to contribute to OA severity, however differences in
musculoskeletal physiology such as smaller knee cartilage volumes in women may also
contribute to this disparity [141, 145, 146]. Lastly, genetics play a clear role in the
etiology of all OA subtypes, where inheritance studies involving twins and siblings have
shown heritability of OA to range from 39-78% [147, 148]. Recent genome-wide
association studies (GWAS) conducted on the global scale have identified various
mutations or single-nucleotide polymorphisms (SNPs) to be linked to OA, including but
not limited to ECM structural components as well as factors involved in synovial joint
development [143, 149].
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1.3.2.2

Metabolic OA

Metabolic dysregulation also acts as a major contributing factor towards osteoarthritic
symptoms in the joint. Increasing evidence suggesting metabolic dysfunction to be a
contributing factor for OA development is bringing awareness to metabolic OA, a
classification of OA based on its pathophysiological phenotype [150]. Metabolic OA is
characterized by its associative factors of hyperglycemia, hormonal imbalance and
elevation of adipokines, as well as metabolic syndrome features such as dyslipidemia,
hypertension and obesity [150, 151]. Notably, disruption of lipid metabolism has been
consistently linked to OA pathology, as seen by proteomic analyses demonstrating a
significant proportion of lipid metabolism proteins to be differentially expressed between
normal and osteoarthritic cartilage [152–156]. Increased levels of circulating saturated
free fatty acids, a result of obesity-induced lipolysis in adipocytes, have also been shown
to contribute to OA pathogenesis [157, 158].

1.4

Nuclear Receptors

Nuclear receptors, a class of transcription factors that modulate gene expression in
response to lipid-soluble ligands, are increasingly studied for their role in
transcriptionally regulating chondrocyte metabolism. Nuclear receptors are activated
upon ligand-binding, where lipophilic substances such as steroid hormones, fatty acids,
cholesterol intermediates, bile acids, and synthetic ligands bind to the ligand-binding
domain, causing a conformational change allowing direct DNA-binding and/or
recruitment of transcriptional machinery [159]. Due to their unique property of being able
to directly interact with DNA and control gene expression, nuclear receptors are
implicated in numerous developmental and homeostatic processes [160]. Additionally,
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nuclear receptors are considered ideal drug targets by the pharmaceutical industry
because synthetic ligand analogs have been developed for almost every nuclear receptor
with a natural ligand [161].

1.4.1

Retinoid X Receptor

The Retinoid X Receptor (RXR) is a nuclear receptor that forms obligate heterodimers
with a large number of other members of the nuclear receptor superfamily, including the
Liver X Receptor (LXR), the Peroxisome Proliferator-Activated Receptor (PPAR), and
the Retinoic Acid Receptor (RAR) [162]. As each of these nuclear receptors are activated
by their respective ligands of cholesterol derivatives (LXR), fatty-acids (PPAR), and alltrans retinoic acid (RAR), RXR exerts a pan-regulatory effect by modulating and
integrating multiple metabolic pathways [163].
Despite recent studies that have greatly advanced our understanding of nuclear receptor
function, in particular heterodimeric partners of RXR, in cartilage development and
homeostasis [164–169], the role of RXR in cartilage health remains to be elucidated. This
is in part due to the complex allosteric interactions between RXR and its dimeric partners
that are not well understood [170]. What is known is that RXR heterodimers can be
permissive or non-permissive in nature. Permissive RXR heterodimers can be activated
by ligands for either partner in the dimer to result in additive or synergistic effects,
whereas non-permissive heterodimers can only be activated by the partner’s ligands and
not by an RXR ligand alone [170].
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1.4.2

Liver X Receptor

The Liver X Receptors (LXRα /NR1H3 and LXRβ /NR1H2) are ligand-activated
transcription factors and members of the nuclear receptor superfamily [171]. Although
initially classified as orphan nuclear receptors, several physiological ligands have since
been identified. Both LXR isoforms form obligate heterodimers with RXR, and upon
ligand binding recruit the necessary transcriptional machinery to regulate expression of
target genes [171], as depicted in Fig 1.4. In the absence of ligands, LXR recruits corepressor complexes that are dissociated and exchanged with co-activators upon receptor
activation [172]. While oxysterols are currently the most widely known endogenous LXR
agonists, D-glucose and D-glucose-6-phosphate have also been shown to activate both
LXR isoforms [173–175].
In addition to natural ligands, numerous potent synthetic LXR ligands exist. The most
commonly used commercially available synthetic ligands include T0901317 and
GW3965, nonspecific and specific LXR agonists, respectively [176–180]. In contrast to
T0901317, which has been shown to modulate not only LXR but also the Farnesoid X
Receptor (FXR), the Pregnane X Receptor (PXR), and the RAR-related orphan receptora (RORa), GW3965 administration demonstrated cross-reactivity with only PXR at less
than 10-fold selective activation compared to LXR [176–180]. As such, GW3965
remains one of the most highly selective LXR agonists and continues to be preferentially
utilized in numerous in vivo and in vitro experiments. However, an isoform-specific
synthetic ligand for LXR remains to be developed.
LXRs are best known for their central roles in regulation of lipid metabolism and
inflammatory signaling [181–183]. LXRs are key regulators of lipogenesis due to their
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ability to upregulate the expression of SREBP1C, the main master regulator of hepatic
lipogenesis, and its downstream target genes [184, 185]. This lipogenic effect of LXR
results in increased levels of hepatic triglycerides, as well as transient increases in plasma
triglyceride levels [184]. However, this increase in plasma triglycerides is eliminated
upon specific LXRβ activation, done through GW3965 administration to LXRα -/- ApoE-/
mice [186]. This suggests that isoform-selective targeting of LXRβ may prove to be more
beneficial in the development of therapeutic drugs for the treatment of various diseases.
In addition to LXR’s regulatory roles in lipid metabolism, LXRs also regulate cholesterol
homeostasis. Specifically, direct LXR target genes are linked to reverse cholesterol
transport, a process by which excess cholesterol is returned to the liver from peripheral
tissues for ultimate excretion in bile [187–189]. Reverse cholesterol transport is
initialized by cholesterol efflux from peripheral cells, a process controlled by ATPbinding cassette cholesterol transporter proteins ABCA1 and ABCG1 [190]. Impaired
expression of genes encoding for these cholesterol transporter proteins has been found in
osteoarthritic chondrocytes in comparison to healthy chondrocytes, suggesting alterations
in cellular lipid metabolism to be a critical causal factor of OA [191].
Interestingly, recent studies have also suggested LXR to possess roles in cartilage that
offer protection against OA. In particular, mice deficient for LXRβ display early OA-like
symptoms, including proteoglycan degradation and prostaglandin-E2 production in the
articular cartilage [192]. Furthermore, when the transcript levels of 48 nuclear receptors
were measured in human OA articular cartilage, both LXRα and LXRβ as well as their
downstream target genes Abcg1, ApoE and ApoD were expressed at significantly lower
levels in comparison to healthy articular cartilage [193]. The administration of synthetic
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Figure 1.4 Ligand activation of LXR/RXR heterodimer. The Liver X Receptor (LXR)
and Retinoid X Receptor (RXR) form permissive obligate heterodimers that can be
activated by LXR ligands, RXR ligands, or both. Endogenous ligands for RXR include 9cis retinoic acids, a metabolite of retinol, whereas endogenous ligands for LXR include
oxysterols, oxidized derivatives of cholesterol. Ligand binding to the nuclear receptor
causes the heterodimeric complex to recruit the appropriate transcriptional machinery to
regulate transcription of target genes.
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Figure 1.4 Ligand activation of LXR/RXR heterodimer
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LXR agonists to these human OA articular cartilage explants suppressed proteoglycan
degradation and restored LXR-activated transcription [192, 193]. However, the specific
molecular roles and mechanisms of LXR in cartilage remain poorly understood.

1.5

Overall Objectives and Hypotheses

Liver X Receptor has been implicated in chondroprotection against OA, however the
exact mechanisms behind this effect remains unknown. Of particular interest to us is the
necessary interaction of LXR with its heterodimeric partner, RXR, in order to recruit the
appropriate transcriptional machinery and regulate downstream gene expression. Both
LXR isoforms form obligate heterodimers in a permissive manner – meaning this
heterodimeric complex may be activated by either LXR ligands, such as oxysterols, or
RXR ligands, such as 9-cis-retinoic acid [171]. It is therefore possible that some of the
effects observed with LXR activation could be due to heterodimeric activation of RXR.
However, RXR’s role in cartilage remains unknown and elucidation of this function
could aid in the understanding of not only LXR’s regulatory function in cartilage but also
provide insight into the roles of other RXR heterodimeric partners. As such, the objective
of my thesis is to elucidate the roles of RXR and LXR in chondrocyte biology and
cartilage health. My governing hypothesis is that LXR and RXR regulate cartilage
development, maturation, and lipid homeostasis.

1.5.1
1.5.1.1

LXR in Endochondral Bone Growth
Objective #1

To determine roles of LXR in chondrocyte differentiation and endochondral bone growth.
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1.5.1.2

Rationale #1

Recent studies have suggested LXR to possess roles in cartilage that offer protection
against OA. In particular, mice deficient for LXRβ display earlier OA-like symptoms,
including proteoglycan degradation and prostaglandin-E2 production in the articular
cartilage [192]. However, the underlying mechanisms of this chondroprotective effect
remain unexplored. Through specific pharmacological activation of LXR in chondrogenic
cultures modeling embryonic bone growth, I will evaluate the role of LXR in
chondrocyte differentiation to elucidate its implications in osteoarthritic changes in
chondrocyte behavior and activity.

1.5.1.3

Hypothesis #1

LXR plays a role in the regulation of chondrocyte differentiation, specifically by
controlling chondrocyte hypertrophy.

1.5.2
1.5.2.1

LXR-Regulated Genes in Embryonic Chondrocytes
Objective #2

To examine the transcriptional regulation of embryonic growth plate chondrocytes by
LXR.

1.5.2.2

Rationale #2

To further understand the mechanisms behind LXR’s role in chondrocyte differentiation
and embryonic bone growth, downstream genes controlled by LXR need to be identified.
Genome-wide expression analysis through Affymetrix microarrays will be conducted to
identify LXR target genes in order to gain insight into its regulatory mechanisms and
signaling pathways. The identification of target genes will further help us understand
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LXR’s function in cartilage development, while pinpointing potential therapeutic targets
for cartilage disorders.

1.5.2.3

Hypothesis #2

LXR activation differentially regulates downstream gene expression to alter growth plate
chondrocyte metabolism and activity.

1.5.3
1.5.3.1

LXR and RXR in Articular Chondrocytes
Objective #3

To identify and validate LXR and RXR target genes in post-natal articular chondrocytes.

1.5.3.2

Rationale #3

Despite certain similarities, post-natal articular chondrocytes differ significantly from
embryonic growth plate chondrocytes in terms of metabolic, proliferative and
differentiation activity. As such, in order to gain further insight into how LXR
transcriptional activity regulates articular chondrocyte metabolism and behavior,
genome-wide expression analysis using Affymetrix microarray will be conducted using
post-natal day 5 articular chondrocytes treated with an LXR agonist. This will be
performed in parallel using chondrocytes treated with an RXR agonist to examine RXRregulated genes, and further elucidate the overlap in RXR and LXR effects in cartilage.

1.5.3.3

Hypothesis #3

LXR and RXR differentially regulate downstream gene expression to alter articular
chondrocyte metabolism and activity.
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Chapter 2

2

Liver X Receptor activation delays chondrocyte hypertrophy
during endochondral bone growth

This chapter has been adapted from:
Sun MM-G, Beier F (2014) Liver X Receptor activation delays chondrocyte hypertrophy
during endochondral bone growth. Osteoarthritis Cartilage 22:996–1006.

2.1

Abstract

Objective: Activation of the Liver X Receptor (LXR) has recently been identified as a
therapeutic strategy for osteoarthritis (OA). Human OA articular cartilage explants show
decreased LXR expression, and LXRβ-null mice display OA-like symptoms. LXR
agonist administration to OA articular cartilage explants suppresses proteoglycan
degradation and restores LXR-activated transcription. We aimed to investigate the effect
of LXR activation on chondrocyte differentiation to elucidate the molecular mechanisms
behind its protection against OA.
Methods: The specific LXR agonist, GW3965, was used to examine the effect of LXR
activation on chondrocyte differentiation. Tibia organ cultures were used to examine the
effect of LXR activation on bone growth and growth plate morphology, followed by
immunohistochemical analysis. In ATDC5 and micromass cultures, chondrocyte
differentiation was examined through cellular staining and proliferation assays. Various
chondrogenic markers were analyzed by qRT-PCR in micromass RNA.
Results: Chondrocyte hypertrophy was suppressed by GW3965 treatment, as shown by
decreased hypertrophic zone length in the tibial growth plate, decreased alkaline
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phosphatase staining in ATDC5 and micromass cultures, and down-regulation of
Col10a1, Mmp13 and Runx2 expression. Increased proliferation in treated ATDC5 cells
and up-regulation of Col2a1 expression in treated micromass cultures suggest
hypertrophy is suppressed secondary to prolonged proliferation. Decreased p57 levels in
treated growth plates suggest this to be due to cell cycle exit delay.
Conclusion: Our findings regarding LXR’s role in cartilage development provide insight
into how LXR activation prevents cartilage breakdown, further solidifying its potential as
a therapeutic target of OA.

2.2

Introduction

Longitudinal bone growth in the body is attributed to the activity of the growth plate in
the process of endochondral ossification, in which a cartilage template intermediate is
formed and then replaced by bone specific matrix [1]. Endochondral ossification begins
with the condensation of mesenchymal cells, which then initiate chondrogenic
differentiation under the control of the transcription factor Sox9 [2, 3]. These
chondrocytes first proliferate while producing extracellular matrix rich in collagen II and
proteoglycan (aggrecan), then exit the cell cycle and undergo hypertrophy starting from
the center of the cartilage anlage [2, 4, 5]. The hypertrophic chondrocytes initiate
mineralization of their matrix and undergo apoptotic cell death [2]. This allows the
invasion of blood vessels, osteoblasts, and osteoclasts to remove the cartilage matrix for
the deposition of bone matrix, ultimately forming the primary ossification center [5, 2].
Postnatally, chondrocytes at the two distal ends of the bone undergo a similar
differentiation process to form the secondary ossification centers [6]. The developing
cartilage that remains between the primary and the secondary ossification centers is
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defined as the growth plate, consisting of distinct cell layers of resting, proliferative and
hypertrophic zones [1, 2]. While many markers of chondrocyte differentiation are known,
many nuclear factors and signaling molecules regulating this process remain to be
elucidated.
Certain characteristics of osteoarthritis (OA) have been found to resemble the
endochondral ossification process [7]. As opposed to growth plate chondrocytes that are
much more dynamic, healthy articular chondrocytes remain in a stable state and do not
differentiate further [8]. However, osteoarthritic articular chondrocytes lose their stable
state and can initiate behavior similar to growth plate chondrocytes, such as proliferation,
terminal differentiation and hypertrophy, and apoptosis [9–12]. Furthermore, proteolytic
enzymes such as matrix metalloproteinase (MMP)-13 and aggrecanases produced by
hypertrophic chondrocytes to degrade their surrounding matrix within the growth plate
are also produced in OA cartilage [13]. As such, it is reasonable to postulate that
signaling molecules involved in the pathogenesis of OA may also be involved in
regulating chondrocyte differentiation of the growth plate [14].
The Liver X Receptors (LXRα/NR1H3 and LXRβ/NR1H2) are nuclear receptors best
known for their central roles in regulation of lipid metabolism and inflammatory
signaling [15–17]. However, recent studies have suggested LXR to possess roles in
cartilage that offer protection against osteoarthritis (OA). LXRβ-null mice display OAlike symptoms, including proteoglycan degradation and prostaglandin-E2 production in
the articular cartilage [18]. Furthermore, human OA articular cartilage explants exhibit
decreased LXRα and LXRβ expression [19]. Interestingly, the administration of synthetic
LXR agonists to human OA articular cartilage explants suppresses proteoglycan
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degradation and restores LXR-activated transcription [18, 19]. However, the cellular and
molecular mechanisms underlying LXR’s protective role in cartilage are not completely
understood.
In this study, we hypothesize that LXR plays a role in the regulation of chondrocyte
differentiation, specifically by controlling chondrocyte hypertrophy. To test our
hypothesis, the specific LXR agonist, GW3965, was used to examine the effect of LXR
activation on different culture systems. Markers of chondrogenic differentiation were
subsequently analyzed at the mRNA and protein level to help elucidate underlying
mechanisms. Our findings show that LXR activation using a synthetic agonist results in
enhanced chondrocyte proliferation and reduced chondrocyte hypertrophy. These results
suggest LXR’s role in regulating endochondral ossification to be a possible mechanism in
protection against OA.

2.3

Materials and Methods

Timed pregnant CD1 mice were purchased from Charles River Laboratories (St.
Constant, QC). All procedures involving mice were conducted following the animal
protocol approved by the University of Western Ontario Animal Care and Use
Committee. All organ culture and cell culture media components were from SigmaAldrich (Oakville, ON), Gibco (Life Technologies Inc, Burlington, ON), and Invitrogen
(Life Technologies Inc, Burlington, ON) unless otherwise stated. The LXR agonist,
GW3965, was purchased from Sigma-Aldrich. All real-time PCR reagents and probes
were purchased from Applied Biosystems (Life Technologies Inc, Burlington, ON).
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2.3.1

Tibia organ culture

Tibiae were isolated from E15.5 CD1 mice of either sex and cultured in media as
previously described [20–23]. Tibiae were then incubated for 6 days. Treatment
commenced the day following tibia isolation (day 1) using dimethylsulfoxide (DMSO)
(Sigma-Aldrich) as the vehicle, and the LXR agonist GW3965 at concentrations of 1 µM,
2 µM, 5 µM and 10 µM. Measurements of bone length were taken on day one prior to
treatment using both the Zeiss Stemi SV6 Stereo Zoom microscope with eyepiece, as
well as the Leica EC3 microscope and Leica Application Suite V3 Software (Leica
Microsystems Inc, Concord, ON). Media with treatment were changed every other day,
and after 6 days another measurement was taken. The calculated difference in tibia length
between time points was used as a measure of bone growth.

2.3.2

Histology

Tibiae explants were rinsed with phosphate buffered saline (PBS) and fixed overnight in
4% paraformaldehyde (PFA) (Sigma-Aldrich). Tibiae were then marked with 2%
mercurochrome, placed in 70% ethanol, and sent for embedding and sectioning at the
Robarts Research Institute, Molecular and Pathology (London, ON). Safranin-O/Fast
Green staining was performed as described with minor modifications [22]. After
dewaxing in xylene and rehydration in a series of graded alcohol washes, sections were
incubated in hematoxylin for 2 min, 0.02% Fast Green (Harleco, Darmstadt, Germany)
for 25 minutes followed by 7 dips in 1% acetic acid solution, and finally 0.1% Safranin-O
(Sigma-Aldrich) for 7 min. Slides were then dehydrated and mounted using a xylenebased mounting media. Histological quantification was performed on stained sections
through the measuring of the length of individual growth plate zones as well as the total
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growth plate. On all sections, the length of the total growth plate was first identified,
followed by the hypertrophic zone and the proliferative and resting zones collectively.
All measurements were done using the distance line tool on Leica Application Suite V3
Software.

2.3.3

Immunohistochemistry (IHC)

Paraffin sections were dewaxed and rehydrated followed by incubation in 3% H2O2.
Sections were then boiled in sodium citrate (pH 6.0), blocked with 5% goat serum in
PBS, and incubated with Kip2/p57 primary antibody (sc-8298, Santa Cruz
Biotechnology, Santa Cruz, CA) at 4°C overnight with secondary antibody subsequently
applied [24].

After colorimetric detection with diaminobenzidine (DAB) (Dako,

Markham, ON) substrate solution, sections were counterstained with methyl green and
mounted. Quantification of IHC was performed by counting all positively stained
(brown) cells within a 58.48 x 107.53 µm area of interest. All values presented were
absolute numbers of positively stained cells in control or GW3965 treated growth plates.
All images were captured using the Leica DFC295 microscope and Leica Application
Suite V3 Software.

2.3.4

ATDC5 cell culture

ATDC5 cells were cultured and induced to differentiate with 1% insulin-transferrinselenium (ITS) (Sigma-Aldrich) the day after plating as described [25–27]. Cells were
plated at a density of 2 x 104 cells/ml in 24-well plates for a period of 18 days. Treatment
was commenced on day 3 with DMSO as the vehicle or 1 µM GW3965. Media including
treatment was changed every other day throughout the entire time-course.
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2.3.5

Proliferation assays

MTT proliferation assay was performed as described with minor modifications [25, 28].
ATDC5 cells were plated at 2 x 104 cells/ml in 24-well plates. Cells were treated with
DMSO or 1 µM GW3965 for a period of 15 days, with media changed every other day.
On days 3, 6, 9, 12, and 15, 1:10 dilution of 5mg/mL MTT (Sigma-Aldrich) in PBS was
added to cells and incubated for 4 h at 37°C. Solubilization using acidified isopropanol
(0.04 M HCl in absolute isopropanol) followed, and the converted dye was quantified
using a Safire plate-reader (Tecan, Männedorf, Switzerland) and XFluor4 software at 570
nm with background subtraction at 650 nm. The absorbance (A570nm-A650nm) correlates
directly to living cell number in ATDC5 cells.
To assess total cell number, direct cell counting was performed. ATDC5 cells plated at
the same density were trypsinized for 2-5 minutes. After neutralizing with media, cell
solution of each well was counted using a hemacytometer. The total number of cells/well
is the counted number x 104, where at least 3 wells/condition were plated and counted on
each day of the time-course.

2.3.6

Micromass culture

Limb buds (forelimb and hindlimb) of E11.5 CD1 mouse embryos were isolated and
segmented, then dissociated in a solution containing puck saline A (PSA), 10% (v/v)
chick serum, and 2% (v/v) dispase (50 caseinolytic units/ml, BD Biosciences, San Jose,
CA) for 1.5 h at 37°C and 100 rpm. The dispase activity was neutralized and a single cell
suspension was extracted as described [29, 30]. After cell counting and a brief
centrifugation, cells were resuspended in micromass media at a concentration of 2.5 x 107
cells/ml and plated into six-well NUNC cell culture plates, at eight 10µl drops/well.
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Plated cells were incubated at 37°C and 5% CO2 for 1 h to allow cell adherence, followed
by the addition of 2 ml/well of micromass media supplemented with 10mM βglycerophosphate, 50 µg/ml ascorbic acid, and the treatment of DMSO or GW3965. Cells
were cultured for a period of 15 days, with media and treatment replenished daily.

2.3.7

Cell staining

Micromass cultures were stained with alcian blue as described [29]. Both micromass
cultures and ATDC5 cell cultures were stained for alkaline phosphatase activity (ALP) as
previously described, with minor modifications [29, 30]. Cells were washed twice with
cold PBS and fixed in 10% formalin for 2 h at room temperature. After a 15 min
incubation in ddH2O, cells were stained with an ALP substrate containing 0.1 mg/ml
naphthol AS-MX phosphate (Sigma-Aldrich), 0.5% N,N-dimethylformamide (SigmaAldrich), and 0.6 mg/ml Red Violet LB salt (Sigma-Aldrich) in 0.2 M Tris-HCl (pH 8.3)
for 45 min in the dark. All cells were washed with tap water and allowed to air-dry before
visualization. All images were captured using the Leica EC3 microscope and Leica
Application Suite V3 Software.
Alcian blue staining in micromass cultures was quantified using the Leica Application
Suite V3 Software. For each time-point of each individual trial, thresholds were selected
for the parameters hue, saturation and intensity using a representative control stain. These
threshold values were set in an attempt to encompass all dark blue nodules within the
micromass, and were applied to all treatment stains within that same time-point. Values
represent the total area (mm2) of the micromass that fell within the threshold.
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2.3.8

RNA isolation and real-time PCR

Total RNA was isolated from micromass cultures using the RNeasy mini kit (Qiagen,
Toronto, ON) on days 3, 6, 9 and 12 according to manufacturer’s instructions. Isolated
RNA was quantified using a Nanodrop 2000 spectrophotometer, and subsequently diluted
to 50 ng/µl. Template RNA was combined with commercially available probes from
Applied Biosystems (Gapdh – Mm99999915_g1; Mmp13 – Mm00439491_m1; Sox9 –
Mm00448840_m1; Col2a1 – Mm00491889_m1; Runx2 – Mm00501580_m1; Col10a1 –
Mm00487041_m1; Cdkn1c – Mm01272135_g1; Ihh – Mm00439613_m1; Pthlh –
Mm00436057_m1) and the TaqMan one-step mastermix kit to make a final volume of 15
µl. Amplified target sequences were detected by the ABI Prism 7900 HT sequence
detection system (Perkin Elmer, Waltham, MA). Expression values from all samples
were normalized to the internal control glyceraldehyde-3-phosphate (Gapdh) using the
delta-delta cycle threshold (ΔΔCT) method.

2.3.9

Protein extraction and Western blotting

Protein was harvested from ATDC5 cell cultures starting on day 3 of culture, then every
3 days thereafter. Cells were briefly washed with cold PBS, then suspended in RIPA
buffer (containing protease inhibitors) and harvested. Following 30 min of incubation on
ice, cell lysates were centrifuged for 25 min at 4°C at 14 000 rpm. The supernatant was
collected and protein concentration was quantified using the Pierce BCA Protein Assay
Kit (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s instructions.
Subsequently, 19 µg of protein was loaded and separated through SDS-PAGE, followed
by protein transfer onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad
Laboratories, Hercules, CA). The membrane was then blocked with 5% BSA-TBST, and
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incubated with primary antibody against p57/Kip2 (ab75974, Abcam, Cambridge, United
Kingdom) and β-actin (A5441, Sigma-Aldrich). After washing in TBST, the membrane
was incubated with goat-anti-rabbit (sc-2004, Santa Cruz), or goat-anti-mouse (sc-2005,
Santa Cruz) IgG-HRP conjugated secondary antibody. Signal visualization was
performed using the Clarity Western ECL Substrate (Bio-Rad) and the Bio-Rad
ChemiDoc MP Imaging System.

2.3.10

Statistical analysis

All data collected were from at least 3 independent trials. Data were expressed as mean
with 95% confidence interval (CI) (upper and lower limit), and p-values < 0.05 were
considered significant. Statistical analysis was performed using one-way or two-way
Anova with the Tukey’s post-hoc test using GraphPad Prism 6.0 (GraphPad software,
San Diego, CA).

2.4
2.4.1

Results
LXR activation alters growth plate morphology ex-vivo

To investigate the effect of LXR activation on longitudinal bone growth, E15.5 tibiae
were isolated and cultured in the presence of a specific LXR agonist, GW3965. Tibiae
treated with varying concentrations of GW3965 (0, 1, 2, 5 or 10 µM) did not reveal
significant changes in growth, although a non-significant trend towards decreased growth
in treated tibiae was observed (Fig. 2.1). To further examine how GW3965 treatment
affected E15.5 tibial growth plates, histological analysis was performed using SafraninO/Fast Green staining [Figure 2.2(A)]. Quantitative measurements of individual growth
plate zones demonstrated the hypertrophic zone to be significantly reduced in length
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Fig. 2.1. Effect of GW3965 on longitudinal bone growth. Mouse tibiae were dissected
at E15.5, grown in culture for 6 days and treated every 48 hours with DMSO as vehicle,
or various concentrations of GW3965. Bone length was measured on days 1 and 6 to
assess longitudinal growth. The values are presented as the mean of 6 independent trials,
with 95% CI.
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Fig. 2.2. Histological analyses of GW3965-treated tibia organ cultures. (A) After 6
days in culture with DMSO as vehicle or different concentrations of GW3965, tibiae
were embedded and sectioned. Sections were stained with Safranin-O/Fast green to
visualize growth plate morphology. Representative images show the different zones of
the growth plate (R+P = resting and proliferating zones, H = hypertrophic zone) (n=6).
Scale bar = 200 µm. (B) Histological quantification was conducted on stained sections by
measuring individual growth plate zones. The values are presented as the mean of 6
independent trials, with 95% CI.
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Figure 2.2 Histological analyses of GW3965-treated tibia organ cultures
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when treated with 1 µM, 5 µM and 10 µM GW3965 [Figure 2.2(B)]. The length of the
total growth plate and the proliferating and resting zones combined remained comparable
between treated and control tibiae [Figure 2.2(B)]. These collective results suggest that
LXR activation suppresses chondrocyte hypertrophy.

2.4.2

The cell cycle exit marker p57 is decreased in GW3965 treated
tibiae

In order to gain insight into the mechanisms underlying the shortened hypertrophic zones
in GW3965 treated tibiae, the cell cycle exit marker p57 was studied using
immunohistochemistry (IHC) [Figure 2.3(A)]. Quantification of p57 IHC demonstrated
that the number of positively stained cells in GW3965 treated growth plate decreased
relative to control [Figure 2.3(B)]. This demonstrates that the suppression of chondrocyte
hypertrophy observed in the tibial growth plate is in part due to a delay in cell cycle exit.

2.4.3

LXR activation results in decreased hypertrophy and increased
proliferation in ATDC5 cells

To further assess the role of LXR activation in endochondral bone growth and
development, ATDC5 cell cultures were used to analyze chondrogenic differentiation
over a continuous time-course. Staining for alkaline phosphatase, a marker of
chondrocyte hypertrophy, was markedly decreased upon treatment with 1 µM GW3965
[Figure 2.4(A)]. This reduction in staining was evident as early as day 9 and persisted
throughout the time-course [Figure 2.4(A)]. Next, the effect of GW3965 on proliferating
chondrocytes was analyzed using the MTT assay and direct cell counting. Our previous
data had shown that MTT values in ATDC5 cells and primary chondrocytes directly
correspond to cell numbers [25, 28]. These methods show cell number to consistently
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Fig. 2.3. Immunohistochemical analyses of p57 protein localization in GW3965treated tibiae. E15.5 tibia organ cultures were cultured for 6 days with DMSO or various
concentrations of GW3965, then fixed and prepared for histology. Incubation of primary
and secondary antibodies was followed by colorimetric visualization with DAB substrate.
(A) Representative images were shown from 4 independent experiments. Scale bar = 200
µm. (B) Quantification of p57 IHC was performed by counting the number of positively
stained (brown) cells within a pre-set box centered on the pre-hypertrophic zone. Data are
presented as the mean of 3 independent trials, with 95% CI.
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Fig. 2.4. Effect of GW3965 on chondrocyte proliferation and hypertrophy in ATDC5
cell culture. ATDC5 cells were plated at a density of 2 ✕ 104 cells/well, induced to
differentiate on day 1, and cultured in the presence of either DMSO or 1 µM GW3965
starting on day 3. (A) Alkaline phosphatase staining was conducted on days 6, 9, 12, 15
and 18 to assess chondrocyte hypertrophy (n=3). Scale bar = 2 mm. (B) On days 6, 9, 12
and 15, cells were incubated with MTT and the absorbance of the converted dye was
measured. Data are presented as the mean of 3 independent trials, with 95% CI. (C) Cells
were trypsinized and counted using a hemocytometer every 3 days starting on day 6.
Values are presented as the mean of 3 independent trials, with 95% CI.
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increase with GW3965 treatment [Figure 2.4(B and C)], suggesting the suppression of
chondrocyte hypertrophy by GW3965 to be secondary to prolonged proliferation.

2.4.4

LXR activation delays chondrocyte differentiation in micromass
cultures

We next used a micromass culture system consisting of mouse embryonic mesenchymal
cells plated in high-density droplets. Compared to ATDC5 cells, this ex-vivo system is a
more physiological model of chondrogenesis. The amount of alkaline phosphatase
staining was reduced in GW3965 treated micromasses [Figure 2.5(A)]. This reduction
appeared to be more dose-dependent than that shown by alcian blue [Figure 2.5(B)].
Alcian blue, a stain that detects the presence of glycosaminoglycans, was decreased upon
treatment of 1 uM GW3965, and slightly more so with 5 µM GW3965 [Figure 2.5(B)].
Quantification using the Leica Application Suite V3 Software demonstrated area of
positive alcian blue staining to decrease with GW3965 treatment [Figure 2.5(C)]. For
both stains, differences between control and treatment became especially apparent
starting on day 6 and persisted throughout the time-course. These ex-vivo results further
validate the effect of LXR activation on suppression of chondrocyte hypertrophy, and
interestingly shows proteoglycan content to also be affected.

2.4.5

LXR activation down-regulates gene expression of late-stage
chondrogenic markers in micromass cultures

To better understand the mechanisms underlying the effect of GW3965 on chondrogenic
differentiation, real-time PCR was performed to examine the expression of various genes
involved in cartilage development. This analysis was performed using RNA extracted
from micromass cultures treated with DMSO or GW3965 (1 or 5 µM). Of the early
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Fig. 2.5. Chondrogenic differentiation of micromass cultures with LXR activation.
E11.5 mouse mesenchymal limb bud cells were plated in micromass cultures and cultured
for 15 days in the presence of either DMSO or GW3965. For all staining, at least 3
independent experiments were used for each time-point, and representative images are
shown. (A) Alkaline phosphatase staining was performed every 3 days starting on day 3 to
examine chondrocyte hypertrophy. Scale bar = 1 mm. (B) Alcian blue content was
examined every 3 days starting on day 3 to assess proteoglycan content and early
chondrogenesis. Scale bar = 1 mm. (C) Alcian blue content was quantified using the Leica
Application Suite V3 Software, where thresholds were chosen for each time-point using
the control image of that time-point. This threshold was then applied to all treatments to
determine the total area of positive staining. Values are represented as the mean with 95%
CI (n=3).
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Figure 2.5 Chondrogenic differentiation of micromass cultures with LXR activation
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chondrogenic markers analyzed, mRNA levels of Col2a1 significantly increased with
GW3965 treatment starting on day 9, while Sox9 and Aggrecan expression remained
unchanged [Figure 2.6(A)]. Chondrocyte hypertrophy markers Runx2, Col10a1 and
Mmp13 all significantly decreased upon treatment with GW3965 on day 12 of culture
[Figure 2.6(B)]. Ihh and Pthlh, major regulators of chondrocyte proliferation and
hypertrophy, decreased with treatment throughout the time-course and on day 12 of
culture, respectively [Figure 2.6(C)]. Although the expression of Cdkn1c demonstrated a
slight increase on day 12 with GW3965 treatment [Figure 2.6(C)], both mRNA and
protein levels of p57 remained unchanged in ATDC5 cells upon treatment
(Supplementary Figure 2.1). These results show that effects of LXR activation on
chondrocyte gene expression are consistent with its effects on histological parameters,
with the exception of p57, potentially demonstrating context-specific expression patterns.

2.5

Discussion

Several nuclear receptors have been identified and shown to be involved in endochondral
ossification through its implications on Sox9 expression and other targets, including
estrogen-related receptors (ERRs), retinoic acid receptors (RARs) and peroxisome
proliferator-activated receptor γ (PPARγ) [31-34]. However, much less is known about
the role of LXR. This study aimed to determine whether LXR actively regulates the
different stages of chondrogenic differentiation. We used a synthetic LXR agonist,
GW3965, to study the specific effects of LXR activation on cartilage development.
The most prominent effect of LXR activation was the decrease in chondrocyte
hypertrophy observed in three different chondrocyte culture systems. Ex-vivo tibia organ
cultures treated with GW3965 showed a significant decrease in hypertrophic zone length.
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Fig. 2.6. Analyses of chondrogenic gene expression in micromass cultures with LXR
activation. Micromass cultures composed of E11.5 mouse limb bud mesenchymal cells
were cultured for 15 days and treated with different concentrations of GW3965. RNA
was isolated every 3 days starting on day 3. Gene expression was analyzed by qRT-PCR
and normalized to Gapdh. Data were expressed relative to values of day 3 control, and
are represented as the mean with 95% CI. (A) The mRNA expression levels of early
chondrogenic markers Sox9, Col2a1, and Acan (n=4 or 6). (B) The mRNA expression
levels of terminal chondrogenic markers Runx2, Col10a1 and Mmp13 (n=4). (C) The
mRNA expression levels of chondrocyte proliferation and hypertrophy regulating factors,
Ckdn1c, Ihh and Pthlh (n=4).
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Figure 2.6 Analyses of chondrogenic gene expression in micromass cultures with LXR
activation
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Similarly, alkaline phosphatase staining was markedly decreased upon LXR activation in
both micromass cultures and in ATDC5 cell cultures. Moreover, the mRNA levels of
major chondrocyte hypertrophy markers Col10a1, Mmp13, and Runx2 were all decreased
with LXR activation. As such, LXR appears to be a negative regulator of chondrocyte
hypertrophy. As chondrocyte hypertrophy is one of the largest contributors to skeletal
growth [35], GW3965’s ability to suppress hypertrophy also explains why a trend
towards a decrease in bone growth was observed with treatment.
The observed decrease in hypertrophic zone length can be speculated to be the result of a
few possible mechanisms. Terminal chondrogenic differentiation could accelerate, and
thus prompt faster turnover of hypertrophic cartilage to bone [36]. Alternatively, overall
differentiation could decrease, resulting in the shortening of each zone [21]. Our data
from proliferation assays (both MTT assays and cell-counts) conducted on ATDC5 cells
suggest another mechanism whereby hypertrophy is delayed through prolonged
proliferation. Although MTT proliferation assay results can only act as correlates to cell
proliferation [37], previous studies using chondrogenic cell lines have shown MTT assay
values to correlate with actual cell numbers [25, 28].
The cyclin-dependent protein kinase inhibitor, p57, inhibits proliferation and acts as both
an inducer and marker of cell cycle exit in chondrocytes transitioning from the
proliferative to hypertrophic state [38]. Immunohistochemical analysis showed the
number of cells positively stained for p57 to be decreased in the growth plate of
GW3965-treated tibiae compared to controls. Together with the observed increase in
proliferation, this suggests LXR activation to enhance chondrocyte proliferation and
delay cell cycle exit and onset of hypertrophic differentiation. In the cell culture systems
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employed in this study, e.g. micromass cultures and ATDC5 cell cultures, GW3965
treatment resulted in different effects on p57 expression. Upon treatment, a slight
increase in mRNA levels was observed in micromass cultures, while mRNA and protein
levels of p57 in ATDC5 cells remained unchanged. This suggests that the authentic onset
of p57 expression is largely dependent on the presence of a proper three-dimensional
spatial architecture of the growth plate that is best emulated by ex-vivo organ cultures and
in-vivo model systems, but not the cell culture models used.
Indian hedgehog (Ihh) and parathyroid hormone like hormone (Pthlh) control
chondrocyte proliferation and differentiation, whereby Ihh, expressed by prehypertrophic and early hypertrophic chondrocytes, stimulates Pthlh production to
maintain proliferation [38]. We saw strong down regulation of Ihh mRNA expression
upon LXR activation. A study by Kim et al. demonstrates LXR activation through
T0901317 or GW3965 to inhibit the expression of hedgehog-target genes in calvaria
organ cultures, which is in line with our findings [39]. Inhibition of hedgehog signaling
has also been shown to decrease the expression of chondrocyte hypertrophy markers and
attenuate OA progression [40]. Thus, repression of Ihh expression could be a key
mechanism responsible for the delayed hypertrophic differentiation seen upon LXR
activation. As Pthlh is in part regulated by Ihh [41, 42], our observed decrease in Pthlh
expression upon LXR activation may be a direct result of a decrease in Ihh expression.
Since the effects of LXR agonists on Ihh expression are much stronger than those on
Pthlh, the net effect of reduced Ihh levels (delayed hypertrophy) appear to be dominating
over those of reduced Pthlh levels.
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Previous studies have demonstrated that LXR activation protects from osteoarthritis
progression [18, 19], but the mechanisms responsible for this protective effect were not
completely understood. Here we show that suppression of hypertrophic differentiation of
articular chondrocytes, which promotes osteoarthritis progression [7, 13, 14], is one such
mechanism. Future studies will have to address the direct target genes of LXR
transcription factors in chondrocytes. Genome-wide profiling of LXR targets has thus far
been performed in liver cells, macrophages and foam cells [43–45]. Among the new
target genes of LXRα identified by Feldmann et al. in foam cells is PARP-1, which
encodes for the enzyme Poly(ADP-ribose) polymerase-1. This enzyme is a ubiquitous
nuclear enzyme that is implicated in various biological processes, including DNA
damage repair [46]. Knockdown of PARP-1 has also shown reduced cell proliferation in
a human embryonic kidney cell line [47]. These findings suggest that PARP-1 could be a
candidate gene up-regulated by LXR activation in chondrocyte differentiation. Future
studies integrating chromatin immunoprecipitation (ChIP) sequencing and gene
expression analyses will help identify LXR target genes in cartilage and elucidate
underlying mechanisms.
In summary, our study demonstrates the novel finding that LXR activation by its
synthetic agonist, GW3965, affects the regulatory processes of chondrocyte
differentiation. In particular, LXR activation suppresses chondrocyte hypertrophy
through the prolongation of cellular proliferation by delaying cell-cycle exit. Further
investigation of the direct targets of LXR will shed light on how LXR regulates this
process. The ability of activated LXR to delay hypertrophic differentiation might be a
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useful attribute in the development of disease-modifying drugs for osteoarthritis
treatment.
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2.7

Supplementary Figures

Supplementary Fig. 2.1. Effect of GW3965 on mRNA and protein levels in ATDC5
cell cultures. ATDC5 cells were induced to differentiate one day after seeding, and
cultured in the presence of either DMSO or 1 µM GW3965 starting on day 3. (A) Total
RNA was isolated every 3 days starting on day 3, and qRT-PCR was used to examine
Cdkn1c gene expression. Expression values were normalized to Gapdh and presented
relative to day 3 control. (B, C) Protein was extracted from ATDC5 cell cultures every 3
days starting on day 3, and the concentration determined by the Pierce BCA assay.
Western blotting was performed using primary antibody against p57 or β-actin.
Densitometric analysis was subsequently conducted using day 3 control as reference, and
values were expressed as p57/β-actin ratio. All results were obtained from 3 independent
trials, and are presented as the mean with 95% CI.
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Chapter 3

3

Liver X Receptor activation regulates lipid homeostasis in
growth plate chondrocytes

These data are currently unpublished, but will contribute to an original first author
manuscript to be submitted for publication:
Sun MM-G, and Beier F. Liver X Receptor activation regulates lipid homeostasis in
growth plate chondrocytes. To be submitted to Osteoarthritis & Cartilage.

3.1

Abstract

Objective: Osteoarthritis (OA) is the most common type of arthritis that causes
debilitating symptoms and decreased quality of life. Currently available treatment options
target symptoms but do not address the underlying issue of joint tissue degeneration. As
such, a better understanding of the molecular mechanisms maintaining cartilage health is
needed for developing novel therapeutic strategies. Liver X Receptors (LXRs) are nuclear
receptors that have been previously shown to offer protection against OA. This is
potentially due to suppression of chondrocyte hypertrophy in endochondral bone growth
in response to LXR activation. In order to better understand the regulatory mechanisms
behind this effect, we aimed to examine LXR’s effects on transcriptional regulation in
growth plate chondrocytes.
Methods: Primary chondrocytes isolated from the long bones of E15.5 mice were treated
with the specific LXR agonist, GW3965, and RNA was isolated for Affymetric
microarray followed by real time qPCR validation. Bioinformatics analyses were
performed

using

Gene

Ontology

(GO)

and

KEGG

pathway

analysis.
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Immunohistochemistry was conducted to examine protein localization of LXR and
identified targets in GW3965-treated E15.5 tibiae compared to control.
Results: Activation of LXR in primary growth plate chondrocytes resulted in differential
regulation of various genes involved in lipid metabolism, including several genes
involved in cholesterol efflux. This transcriptional regulation was compared to LXR
activation in immature murine articular chondrocytes (IMACs), which revealed similar
roles in lipid homeostasis. Immunohistochemical analysis of LXR and its identified
targets Abca1 and Srebf1 revealed preferential protein localization to pre-hypertrophic
and resting chondrocytes in GW3965-treated tibial growth plate compared to control.
Conclusion: Our findings show for the first time that LXR activation alters lipid
metabolism in growth plate chondrocytes, in part through activation of markers
responsible for cellular cholesterol efflux. This provides insight into potential
mechanisms through which LXR regulates cellular metabolism to alter chondrocyte
behavior and phenotype.

3.2

Introduction

Osteoarthritis (OA) is a prevalent degenerative joint disease that globally affects 10% of
men and 18% of women over the age of 60 [1, 2]. Currently available treatment options
merely alleviate symptoms and attempt to improve function through approaches such as
joint replacement surgery, but do not address the underlying cause [3]. Thus, there is an
urgent need for a better understanding of the cellular and molecular mechanisms that
contribute to the pathogenesis of OA. Osteoarthritis is a multifactorial disease with a
complex causative and progressive process. The contributing sources to the
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pathophysiology of primary OA include age, genetics, gender, weight and metabolism,
whereas secondary OA is primarily attributed to joint injury [4, 5]. Although OA may
affect tissues of the entire joint, the characterizing feature of OA is the progressive loss of
the structure and function of the articular cartilage [5, 6]. Cartilage degradation in OA is
generally due to the loss of the balance between synthesis and degradation of the
extracellular matrix (ECM) responsible for maintaining cartilage homeostasis and
function, and changes in chondrocyte phenotype also contribute to this pathology [5, 7,
8].
Certain cellular and molecular events in endochondral bone formation have been found to
be recapitulated in OA pathogenesis, where disruptions in chondrogenic differentiation
can lead to the onset of OA [9]. In particular, ectopic chondrocyte hypertrophy within the
articular cartilage has been shown to act as an OA-promoting factor [9-11]. This is
demonstrated by protection against injury-induced OA in mice lacking drivers of
chondrocyte hypertrophy such as Runx2 or Hif2α [12–14]. It remains unclear whether it
is chondrocyte hypertrophy itself, or simply the induction of hypertrophy-associated
genes, or the combination of both that contributes to cartilage degeneration in OA [15].
Nevertheless, the differentiation and phenotypic changes that developing growth plate
chondrocytes undergo are usually resisted in articular chondrocytes, allowing for a stable
and permanent structure for joint articulation [16]. Better understanding of the regulatory
mechanisms that control the phenotypic disparity between growth plate and articular
chondrocytes can help shed light on the cellular changes that initiate this transition.
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Nuclear receptors are a class of transcription factors activated by small lipophilic
substances to regulate numerous developmental and homeostatic processes [17]. Previous
studies from our laboratory and others have identified nuclear receptors to play important
roles in cartilage biology and osteoarthritis [18-23]. In particular, our work has
demonstrated activation of the Liver X Receptor (LXR) to regulate various lipid
metabolic processes within post-natal immature murine articular chondrocytes (IMACs)
[19]. We further showed LXR activation to suppress chondrocyte hypertrophy during
endochondral bone growth, formulating a novel potential underlying mechanism of
LXR’s protection against OA [23]. However, the signaling pathway behind this
suppression remains to be elucidated. Furthermore, it is unclear whether LXR’s
regulation of lipid metabolism in IMACs also occurs in growth plate chondrocytes to lead
to this suppression of hypertrophy.
In this study, we hypothesize that LXR plays a role in the regulation of lipid metabolism
in developing growth plate chondrocytes. We performed microarray analyses on RNA
extracted from primary chondrocytes isolated from embryonic day 15.5 (E15.5) mouse
long bones. Differentially regulated genes were subsequently validated at both the mRNA
and protein level, and we show changes in gene expression after LXR agonist treatment
to primarily affect lipid metabolism. We also show for the first time LXR’s ability to
regulate target protein localization within the developing growth plate. These results
suggest LXR’s regulation of chondrocyte differentiation may be due to their role in
altering the lipid metabolic profile of growth plate chondrocytes.
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3.3
3.3.1

Methods
Animals and materials

All procedures involving mice were performed in accordance to the Canadian Council on
Animal Care (CCAC), and followed the animal care and use protocol approved by the
Council on Animal Care at Western University (Canada). Timed pregnant CD1 mice
were obtained from Charles River Laboratories. The LXR agonist, GW3965, and all
associated real-time reagents and primers were obtained from Sigma-Aldrich. All organ
culture and cell culture media components were obtained from Sigma-Aldrich and
Thermo Fisher Scientific, unless otherwise stated.

3.3.2

Primary cell culture

Primary chondrocytes were isolated from long bones of E15.5 CD1 mice with no
differentiation of sex (femur, tibia, radius, ulna, fibula, humerus, scapula) and cultured as
previously described with modifications [24]. To remove muscle and other associated
tissue, isolated long bones were subjected to a 15 minute incubation in 500 µL of trypsin
at 37°C under agitation. This was followed by a 1.5-2 hour incubation in Collagenase-P
(3 mg/mL, Roche) diluted in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) at 37°C under 5% CO2. Digested cells
were strained with a 40 µm cell strainer, then plated on 1.2% agarose. Cells were allowed
to recover overnight before commencement of treatment using dimethylsulfoxide
(DMSO) as vehicle control, or LXR agonist (GW3965) at 1 µM concentration for a
period of 24 hours.
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3.3.3

RNA isolation and microarray analyses

Following treatment, RNA was isolated from primary chondrocytes using TRIzolä
(Invitrogen) as per manufacturer’s instructions and as previously described [19]. In brief,
cell homogenization with TRIzolä was followed by the addition of chloroform for phase
separation and the upper aqueous phase was removed. RNA was precipitated using 100%
isopropanol and washed with 70% ethanol. RNA was allowed to air-dry prior to
resuspension in RNAse-free water, then quantified using a Nanodrop 2000
spectrophotometer (Thermo Fisher Scientific). RNA integrity was determined using the
Agilent 2100 Bioanalyzer, and samples with RNA integrity number (RIN) greater than 8
was used for microarray analyses at the London Regional Genomics Centre, Robarts
Institute.
Total RNA (200 ng/uL) from three independent cell culture experiments underwent 2
rounds of amplifications, then labeling and hybridization to Affymetrix GeneChipä
Mouse Gene 2.0 ST Array (Thermo Fisher Scientific) containing probe sets representing
> 28,000 coding transcripts, as previously described [19]. The complete microarray data
set will be deposited at the publically accessible Gene Expression Omnibus (GEO)
database, and NCBI accession number provided.

3.3.4

Bioinformatics analyses

Microarray data was analyzed using the Partek Genomics Suite v6.6, where probe data
was normalized and annotated, and ANOVA conducted to identify differentially
expressed genes between control and treated conditions. Genes with p<0.05 and a
minimum of 1.5-fold change were considered significant and used for subsequent gene
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list creation and bioinformatics analyses. Gene Ontology (GO) and Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis was performed to generate GO term
and pathway enrichment. Data was prioritized based on enrichment score (negative
natural log of the enrichment p-value) to indicate hierarchy of level of gene
representation in GO terms and KEGG pathways.

3.3.5

Real-time quantitative polymerase chain reaction (RT-qPCR)

A subset of RNA isolated from E15.5 primary chondrocytes was used for gene
expression analysis through real-time quantitative PCR, as previously described [19, 23,
25]. Complimentary DNA (cDNA) synthesis was conducted using the iScriptä cDNA
Synthesis Kit with 500 ng of starting RNA (Bio-Rad Laboratories), and combined with
50 µM of forward and reverse primers (for primer sequences, please see Supplementary
Table 1) as well as iQä SYBRÒ Green Supermix (Bio-Rad Laboratories). Expression
values were normalized to the internal control Beta-actin (Actb), calculated using the
DDCT method, and expressed relative to control cells treated with DMSO.

3.3.6

Immunohistochemistry

Immunohistochemistry was conducted as described with minor modifications [19, 23].
Tibiae isolated from E15.5 CD1 mice were fixed overnight with 4% paraformaldehyde
(PFA) (Sigma-Aldrich), and embedded and sectioned at the Molecular Pathology Core
Facility, Robarts Institute. Paraffin sections were dewaxed and carried through a series of
rehydration steps, followed by incubation in 3% H2O2. Antigen retrieval was performed
with 0.1% Triton X-100 for 11 minutes, then slides were blocked with 5% goat serum in
phosphate-buffered saline (PBS), and incubated overnight at 4°C with primary antibodies
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against LXRa/b (sc-377260, Santa Cruz Biotechnology), Abca1 (PA1-16789, Thermo
Fischer Scientific), or Srebp1 (PA1-337, Thermo Fischer Scientific). Secondary antibody
incubation was followed by colorimetric detection with diaminobenzidine (DAB)
substrate-chromogen solution (Dako Omnis, Agilent) and counterstaining with methyl
green solution.

3.3.7

Statistical Analysis

All data were collected from at least three independent experimental trials. Data were
represented as mean ± 95% confidence intervals (CI), and p-values less than 0.05 were
considered significant. Statistical analysis was performed using a parametric, unpaired
two-tailed Student’s t-test using GraphPad Prism 6.0.

3.4
3.4.1

Results
Differential gene expression in response to LXR agonism in
growth plate chondrocytes

Our laboratory previously reported LXR activation through GW3965 treatment to result
in delayed chondrocyte hypertrophy in endochondral bone growth [23]. In order to
further understand the regulatory role of LXR in chondrocyte hypertrophy and growth
plate development, we performed microarray analyses for differential gene expression in
E15 primary chondrocytes treated with the LXR specific agonist, GW3965, for a period
of 24 hours. Expression of 30 annotated genes were found to be significantly changed in
response to LXR activation, with 7 genes down-regulated and 23 genes up-regulated.
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Genes upregulated most highly with LXR activation include those encoding ATP-binding
cassette sub-family G member-1 (Abcg1), ATP-binding cassette sub-family A member-1
(Abca1), sterol regulatory element-binding transcription factor 1 (Srebf1/Srebp1),
Lysophosphatidylcholine Acyltransferase 3 (Lpcat3), Stearoyl-CoA desaturase (Scd1),
and Acyl-CoA synthetase (Acsl3) [Fig. 3.1(a)]. Induction of these most highly changed
genes was subsequently validated through quantitative real-time PCR (Fig. 3.2). Realtime results revealed consistent up-regulation of target gene expression with GW3965
treatment, which is in-line with our microarray results.
In order to gain a better understanding of the functional roles of these differentially
regulated genes, we conducted Gene Ontology and KEGG pathway analyses. This allows
for the identification of represented cellular components, molecular functions, and
biological processes, as well as associated pathways. The top 10 gene ontology groups
prioritized by enrichment scores are primarily biological processes involved in lipid
metabolism, including cholesterol metabolic process, lipoprotein metabolic process, and
plasma lipoprotein particle organization [Fig. 3.1(b)]. Similarly, the top 10 KEGG
pathways prioritized by enrichment scores indicate differentially regulated genes to be
represented in various pathways of lipid homeostasis, including fatty acid metabolism,
peroxisome proliferator-activated receptor (PPAR) signaling pathway, and adipocytokine
signaling pathway [Fig. 3.1(c)]. Collectively, these analyses suggest the primary effect of
LXR activation in growth plate chondrocytes to be control of cellular lipid homeostasis.
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Fig. 3.1. Microarray analyses of differential gene expression in GW3965-treated
primary chondrocytes. (A) RNA was isolated from E15 primary chondrocytes treated
with either DMSO or 1 µM GW3965 for 24 hours and analyzed by Affymetrix
microarray. N=3. (B) Gene Ontology (GO) groups were categorized using Partek and
prioritized by enrichment scores. The top 10 groups and the number of regulated genes
included in each GO group are shown. (C) KEGG pathway annotations prioritized
according to enrichment scores.
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A
Differntially expressed genes in 24 h GW3965-treated
chondrocytes (Selected)
Gene

GW3965 vs Control
Fold Change

Abcg1

5.68

Abca1

3.67

Srebf1

2.64

Lpcat3

1.86

Scd1

1.63

Acsl3

1.53

B

C

Figure 3.1 Microarray analyses of differential gene expression in GW3965-treated
primary chondrocytes
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Fig. 3.2. Real-time validation of differentially expressed genes in GW3965-treated
E15 chondrocytes. RNA was isolated from E15 primary chondrocytes treated with
either DMSO or 1 µM GW3965 for 24 hours, and quantitative real-time PCR was
performed. The six most significantly up-regulated genes (selected) identified from the
microarray, Abca1, Abcg1, Srebf1, Lpcat3, Scd1, and Acsl3, all demonstrated similar
elevation in gene expression through quantitative real-time PCR. N=5, mean ± 95% CI.
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Figure 3.2 Real-time validation of differentially expressed genes in GW3965-treated E15
chondrocytes
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3.4.2

LXR activation in growth plate and articular chondrocytes regulate
similar lipid metabolic processes

To examine whether LXR activation through GW3965 results in similar gene expression
patterns in growth plate chondrocytes and immature articular chondrocytes, we compared
differentially expressed genes in each culture system. Of the 30 up or down-regulated
genes in GW3965-treated E15 chondrocytes, nine were found to be shared with genes
regulated by GW3965 in the IMAC cultures [Fig. 3.3(a)]. The nine commonly changed
genes are among the most up-regulated in both culture systems, and are mainly involved
in lipid metabolic processes as well as cholesterol transport [Fig. 3.3(b)]. However, of the
133 genes differentially regulated by LXR activation in IMAC cultures, 124 identified
genes were unique to this cell-type [Fig. 3.3(a)]. These data suggest LXR to exert similar
lipid homeostatic functions in both embryonic and post-natal chondrocytes, while
regulating molecular functions unique to the maturation stage of chondrocytes.

3.4.3

LXR activation alters LXR protein localization in the growth plate

To gain insight into the effect of LXR activation on the protein localization of LXR
within the growth plate, immunohistochemical analysis was performed on E15.5 tibiae
cultured in the presence of GW3965. Interestingly, despite being expressed throughout
the growth plate in the control tibia, positive staining for LXR appeared to be more
concentrated to the pre-hypertrophic and resting zones with treatment of GW3965 (Fig.
3.4). Closer examination at 40x magnification revealed positive staining for LXR to be
localized to the nucleus. These immunohistochemical results suggest LXR activation to
exert self-regulatory mechanisms based on chondrocyte differentiation phenotype.
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Fig. 3.3. Comparison of differentially expressed genes in GW3965-treated E15
primary chondrocytes and GW3965-treated IMAC cultures. Genes up or downregulated in GW3965-treated iMAC cultures were compared to genes up or downregulated in GW3965-treated E15 primary chondrocytes. (A) Of the 133 genes
differentially expressed in the IMAC cultures, 9 were also differentially expressed in the
E15 primary chondrocytes. N=3. (B) The 9 common gene symbols, gene titles and their
respective fold-changes are shown.
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A
iMACs$

E15 Chondrocytes$$

124$

9$

21$

B
Gene$Symbol
Mylip
Gramd1b
Lpcat3
Acsl3
Scd2
Srebf1
Abcg1
Scd1
Abca1

Gene$Title
Myosin.regulatory.light.chain.interacting.protein
GRAM.domain.containing.1B
Lysophosphatidylcholine.acyltransferase.3
AcylGCoA.synthetase.longGchain.family.member.3
StearoylGCoenzyme.A.desaturase.2.
Sterol.regulatory.element.binding.transcription.factor.1
ATPGbinding.cassette,.subGfamily.G,.member.1
StearoylGCoenzyme.A.desaturase.1
ATPGbinding.cassette,.subGfamily.A,.member.1

Fold$Change
iMACs
2.52304
2.53632
2.82565
3.7258
4.25469
5.08012
5.38479
9.05198
10.6707

E15
2.04233
1.58205
1.85742
1.53432
1.53874
2.64691
5.68304
1.63351
3.66906

Figure 3.3 Comparison of differentially expressed genes in GW3965-treated E15
primary chondrocytes and GW3965-treated IMAC cultures
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3.4.4

LXR activation alters localization of metabolic targets in the
growth plate

We next conducted validation of differentially regulated genes upon LXR activation at
the protein level through immunohistochemical analysis of GW3965-treated tibiae. For
both Abca1 and Srebp1, protein localization appears to become more restricted to the prehypertrophic and resting zones, mirroring what was observed with LXR (Fig. 3.5, Fig.
3.6). Positive staining of Abca1 was observed to be localized to the nucleus, the
perinuclear area, and the cytoplasm on the subcellular level (Fig 3.5). In contrast,
subcellular localization of Srebp1 appears to be mainly nuclear. Taken together, these
findings suggest LXR targets Srebp1 and Abca1 to be regulated in a similar manner as
LXR upon LXR activation.
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Fig. 3.4. Effect of GW3965-treatment on LXR localization in the growth plate.
Mouse tibiae were dissected at E15.5, grown in culture for 6 days and treated every 48
hours with DMSO or 1 µM of GW3965, then fixed and prepared for histology.
Immunohistochemical analyses were conducted for LXR. Representative images show
positive staining of LXR to be more concentrated to the resting and pre-hypertrophic
zones in GW3965-treated growth plates compared to control. Subcellular localization of
LXR is mainly nuclear. N=4, scale bar = 100µm.
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Figure 3.4 Effect of GW3965-treatment on LXR localization in the growth plate
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Fig. 3.5. Effect of LXR activation on Abca1 localization in the growth plate. Mouse
tibiae were dissected at E15.5, grown in culture for 6 days and treated every 48 hours
with DMSO or 1 µM of GW3965, then fixed and prepared for histology.
Immunohistochemical analyses were conducted for Abca1. Representative images show
positive staining of Abca1 to be more concentrated to the resting and pre-hypertrophic
zones in GW3965-treated growth plates compared to control. Subcellular localization of
Abca1 appears to be nuclear, perinuclear, and cytoplasmic. N=4, scale bar = 100µm.
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Figure 3.5 Effect of LXR activation on Abca1 localization in the growth plate
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Fig. 3.6. Effect of LXR activation on Srebp1 localization in the growth plate. Mouse
tibiae were dissected at E15.5, grown in culture for 6 days and treated every 48 hours
with DMSO or 1 µM of GW3965, then fixed and prepared for histology.
Immunohistochemical analyses were conducted for Srebp1. Representative images show
positive staining of Srebp1 to be concentrated to the resting and pre-hypertrophic zones
in GW3965-treated growth plates compared to control. Subcellular localization of Srebp1
appears to be mainly nuclear. N=4, scale bar = 100µm.
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Figure 3.6 Effect of LXR activation on Srebp1 localization in the growth plate
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3.5

Discussion

Previous studies have demonstrated LXR to play key functions in coordinating wholebody lipid homeostasis through highly metabolically active tissues such as the liver [26,
27]. However, much less is known regarding its roles in regulating lipid metabolism in
cartilage. LXR’s potential therapeutic implications in OA has been clearly demonstrated
by its chondroprotective effects in cartilage and in suppressing hypertrophic
differentiation of developing chondrocytes [21, 23], however the underlying mechanisms
behind these effects remain unknown. In the present study, we performed microarray
analysis to examine transcriptional regulation by LXR in growth plate chondrocytes, and
show for the first time that LXR activation is involved in regulating lipid homeostasis
within growth plate chondrocytes.
Our microarray analysis revealed several essential proteins of reverse cholesterol
transport to be amongst the most up-regulated genes identified in response to LXR
activation. Abca1 and Abcg1 encode members of the ABC family of membrane
transporters that promote transfer of cellular cholesterol to acceptor proteins in peripheral
cells such as macrophages [28, 29]. Abca1 and Abcg1 are direct targets of LXR in human
macrophages and keratinocytes [30–33], and can be induced by treatment of synthetic
LXR ligands to result in decreased atherosclerosis pathology stemming from excessive
cholesterol accumulation [34, 35, 32, 36]. Indeed, imaging mass spectrometry has shown
cholesterol accumulation in the superficial area of human osteoarthritic cartilage [37],
and cholesterol efflux gene expression to be decreased in human osteoarthritic
chondrocytes [38]. Given our previous and current findings regarding LXR’s role in
developing chondrocytes, it is possible that LXR’s protective effect in OA is mediated in
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part by their ability to increase cholesterol efflux and suppress chondrocyte hypertrophy
[23]. Our microarray results suggest LXR activation to exert similar lipid metabolic
regulation in both growth plate and articular chondrocytes, and several studies have
functionally linked this genetic regulation with changes in chondrocyte phenotype.
Specifically, previous work from our lab has shown cholesterol administration to result in
increased bone growth and chondrocyte enlargement similar to hypertrophy [20].
Additionally, statin treatment and subsequent lowering of cholesterol has been shown to
have anabolic effects on chondrocytes, and was able to rescue chondrodysplasia
phenotypes induced by FGFR3 mutation [39].
Similar to Abca1, our findings demonstrate LXR activation to result in significantly
increased Srebp1 gene expression with protein localization mirroring LXR within the
growth plate. Srebp1 is a transcription factor known for its role in regulating lipogenic
enzymes such as Scd1, the rate limiting enzyme in the synthesis of monounsaturated fatty
acids from saturated fatty acids [40]. LXR’s ability to up-regulate Srebp1 may seem
counterintuitive given the latter’s lipogenic nature, however studies have shown oleoylCoA to be an essential substrate for cholesterol esterification [41]. Since Srebp1-directed
induction of Scd1 is required for the synthesis of oleoyl-CoA, it appears that the LXRSrebp1-Scd1 axis acts as a cholesterol sensor to decrease cellular accumulation of free
cholesterol in order to diminish its harmful effects [42]. Our immunohistochemical
results showing similar protein localization of LXR and Srebp1 within the growth plate
support this proposed mechanism.
Immunohistochemical analysis revealed LXR to be widely distributed in the embryonic
growth plate, yet more localized to the pre-hypertrophic and resting zones upon
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activation with specific agonist GW3965. Several studies have reportedly identified LXR
response elements (LXRE) in the Lxra promoter of human macrophages and mouse
adipose tissue, suggesting LXRs to possess tissue-specific autoregulatory functions [43–
45]. Although no such autoregulation has been reported in chondrocytes thus far, it is
possible that GW3965-treatment resulted in further preferential activation of LXRa in the
pre-hypertrophic and resting chondrocytes. The underlying cause for increasing the level
of LXRa specifically in these chondrocytes remains to be determined.
In summary, our study shows for the first time that LXR activation by its specific
synthetic agonist, GW3965, differentially regulates genes involved in lipid metabolism in
growth plate chondrocytes. Specifically, the LXR-Srebp1-Scd1 axis was identified to be
a potential protective mechanism employed by LXR to maintain cellular cholesterol
homeostasis. Further studies are needed to functionally validate these lipid metabolic
changes in response to LXR activation in both the normal and diseased state. Better
understanding of LXR’s role in this context will help shed light on the link between lipid
homeostasis and the maintenance of chondrocyte health.
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Chapter 4

4

Nuclear receptors regulate lipid metabolism and oxidative
stress markers in chondrocytes

This chapter has been adapted from:
*Ratneswaran A, *Sun MM-G, Dupuis H, Sawyez C, Borradaile N, and Beier F (2017)
Nuclear receptors regulate lipid metabolism and oxidative stress markers in
chondrocytes. J Mol Med 95:431–444. *Contributed equally

4.1

Abstract

Objective: Joint homeostasis failure can result in osteoarthritis (OA). Currently, there are
no treatments to alter disease progression in OA, but targeting early changes in cellular
behaviour has great potential. Recent data show that nuclear receptors contribute to the
pathogenesis of OA and could be viable therapeutic targets, but their molecular
mechanisms in cartilage are incompletely understood. This study examines global
changes in gene expression after treatment with four nuclear receptor agonists implicated
in OA (LXR, PPARd, PPARg and RXR).
Methods: Murine articular chondrocytes were treated with agonists for LXR, PPARd,
PPARg, or RXR and underwent microarray, qPCR, and cellular lipid analyses to evaluate
changes in gene expression and lipid profile. Immunohistochemistry was conducted to
compare two differentially expressed targets (Txnip, Gsta4) in control and cartilagespecific PPARd knockout mice subjected to surgical destabilization of the medial
meniscus (DMM).
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Results: Nuclear receptor agonists induced different gene expression profiles with many
responses affecting lipid metabolism. LXR activation downregulated gene expression of
proteases involved in OA, whereas RXR agonism decreased expression of ECM
components, and increased expression of Mmp13. Functional assays indicate increases in
cell triglyceride accumulation after PPARg, LXR and RXR agonism but a decrease after
PPARd agonism. PPARd and RXR downregulate the antioxidant GSTA4, and PPARd
upregulates Txnip. WT, but not PPARd-deficient mice display increased staining for
Txnip after DMM.
Conclusion: Collectively, these data demonstrate that nuclear receptor activation in
chondrocytes primarily affects lipid metabolism. In the case of PPARd this change might
lead to increased oxidative stress, possibly contributing to OA-associated changes.

4.2

Introduction

Dysregulation of joint homeostasis can result in osteoarthritis (OA), a collective of
heterogeneous pathologies culminating in joint failure. OA presents with similar
pathological end points but mechanisms of initiation and progression vary among
subtypes of this disease, which is one of the leading causes of disability worldwide [1,2].
Its varied presentation influences whether it is symptomatic or not, and even whether it
can be diagnosed radiographically. Multiple tissues such as the articular cartilage,
subchondral bone, synovium, meniscus, and fat pads are involved in this condition, and
initiation of this disease can stem from mechanical, metabolic, or age-associated factors,
although none of these are mutually exclusive.
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The main function of cartilage is to act as a shock absorber, mediating load bearing
through the influx and efflux of water attracted to the proteoglycan aggregates of the
extracellular matrix, and through the tensile strength conferred by collagen fibril
organization [3]. Although cartilage cells contribute to a small percentage of the volume
of the entire joint, they are sensitive to external factors and respond with changes in gene
expression affecting OA, thus underscoring their importance in joint homeostasis.
Metabolic OA has been classified as a distinct subtype of OA associated with disorders
such as dyslipidemia, hypertension and obesity [4]. Imbalances in systemic lipid and
cholesterol metabolism, nutrient exchange, accumulation of advanced glycation end
products, and increases in adipokines contribute to this condition. Changes in lipid
metabolism, in particular, may directly affect joint homeostasis through ectopic lipid
deposition in chondrocytes [4-6]. In fact, both chondrocyte-specific cholesterol
accumulation and high fat diet have caused increased disease severity in murine models
[7-9]. Altogether these data suggest direct regulation of cartilage homeostasis by lipid
metabolism.
Nuclear receptors are a class of proteins that are activated by small molecule ligands and
can up or downregulate the expression of target genes through the recruitment of cofactors. They have been reported as attractive potential targets for pharmacological
therapy because of their ability to bind synthetic or natural ligands that regulate
transcriptional activity [10]. As such, synthetic agonists for nuclear receptors have been
developed to target metabolic conditions such as dyslipidemia, atherosclerosis, and
diabetes [11,12]. PPARs (peroxisome proliferated activated receptors) are typically
involved in the control of lipid metabolism and activated by the binding of endogenous
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fatty acids, whereas LXR (liver X receptor) is principally involved in cholesterol
metabolism. Recently, we have shown that cartilage-specific ablation of the gene
encoding the nuclear receptor PPARd has a protective effect on cartilage after surgical
induction of OA, demonstrating that PPARd promotes post-traumatic OA. Conversely
PPARg and LXR are protective and necessary for normal joint function and skeletal
development [13-16]. Interestingly, all three of these receptors act in heterodimers with
the common partner RXR, positioning RXR at the centre of a complex network of
nuclear receptors. All of these proteins are expressed in cartilage [17,18,15]. However,
the mode of action of these proteins in cartilage is largely unknown, and since they are
transcription factors, identification of their target genes is essential to understand their
specific roles and to evaluate their value as therapeutic targets. Here we attempted to
identify these target genes in a genome-wide manner.
In this study we have used microarray analysis paired with functional validation to
identify gene targets of LXR, PPARg, PPARd and RXR in articular chondrocytes, in
order to elucidate their potential role in OA pathogenesis. There is strong evidence
implicating the involvement of nuclear receptors in the progression or prevention of OA,
and here we provide insight as to how they may be involved in altering the gene
expression profile and phenotype of mature, healthy chondrocyte cultures. We are also
the first, to our knowledge, to quantify changes in neutral lipid and free cholesterol mass
in chondrocytes in vitro. This information is essential in uncovering the early changes
that occur in chondrocytes before irreversible phenotypic changes within the joint, and is
vital since we currently have no effective biomarkers or treatment to alter the course of
OA progression. Our data demonstrate that changes in gene regulation after nuclear
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receptor agonist treatment primarily affect lipid metabolism, suggesting a close link
between lipid metabolism within chondrocytes and the progression of OA.

4.3

Methods

4.3.1

Primary cell culture and isolation

Immature murine articular chondrocytes (IMACs) were isolated from the femoral head,
femoral condyle, and tibial condyles of 5-6 day old CD1 mice of either sex (Charles
River Laboratories) as per [19]. The tissue was then subjected to one hour (3 mg/ml)
followed by 24 hour (0.5 mg/ml) incubations in Collagenase D diluted in Dulbecco’s
Modified Eagles Medium supplemented with 2 mM l-glutamine, 50 U/ml penicillin and
0.05 mg/ml streptomycin at 37°C under 5% CO2. The tissue fragments were then
agitated, and cells were isolated and cultured [19]. On the seventh day after isolation,
cells were treated with either PPARd agonist (GW501516), PPARg agonist
(Rosiglitazone), LXR agonist (GW3965), RXR agonist (SR11237), or control (DMSO),
all at concentrations of 1 µM for 72 hours. Pyruvate dehydrogenase kinase (PDK)
inhibition studies were done using these nuclear agonist treatments and one of two
inhibitors

at

5µM:

dichloroacetate

(DCA,

pan-PDK

inhibitor)

or

diisopropylaminedichloroacetate (DADA, PDK4 inhibitor), or vehicle control (water).

4.3.2

RNA extraction, purification and RT-qPCR

Total RNA was isolated from cells using TRIzolÒ (Invitrogen). Cells were lysed in
TRIzolÒ reagent, phases were separated using chloroform (20%), and supernatant was
removed. RNA was precipitated using 100% isopropanol (0.5%) and washed using 70%
ethanol followed by air-dry and resuspension in RNAse free water, as per manufacturer’s
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instructions. RNA was quantified using a Nanodrop 2000 spectrophotometer. RNA
integrity was confirmed with Aligent 2100 BioAnalyzer Data Review Software
(Wilmington, DE) at the London Regional Genomics Centre. Samples with RNA
integrity number (RIN) values greater than 8 were used for microarray analysis.
Real-time PCR (RT-qPCR) was performed as per [16]. In brief, qPCR was performed
using a One-Step RT qPCR Master Mix kit and TaqMan Gene Expression Assays
(Applied Biosystems), with 40 cycles on an ABI Prism 7900HT sequence detector
(PerkinElmer), or on a Bio-Rad CFX384 RT-PCR system with 15 µl reaction volumes of
iQ SYBR Green Supermix (Biorad) with diluted cDNA equivalent to 500 ng of input
RNA per reaction, as well as 50 µM forward and reverse primers [20]. Probes for
Acan(Mm00545794_m1),

Actb

(Mm02619580_g1),

Adamts4(Mm00556068_m1),

Adamts5 (Mm00478620_m1), Angptl4(Mm00480431_m1), Col2a1 (Mm01309565_m1),
Fabp3(Mm02342495_m1), Fabp4(Mm00445878_m1), LPL(Mm00434764_m1), Mmp2
(Mm00439498_m1),

Mmp3

(Mm00440295_m1),

Mmp13(Mm00439491_m1),

Pdk4(Mm01166879_m1), Sox9 (Mm00448840_m1) were purchased from Life
Technologies. Gene expression was normalized relative to ActB or 18S (viability studies
only). Relative gene expression was calculated using the DDCt method [21] as described
[22].

Statistical analysis was conducted using GraphPad Prism 6.0. Values were

transformed, and a one-way analysis of variance (ANOVA) was performed followed by
Tukey’s multiple comparisons tests.
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4.3.3

Microarray and data analysis

Total RNA (200 ng per sample) was subject to 2 rounds of amplification followed by
labeling and hybridization to Affymetrix GeneChip® Mouse Gene 2.0 ST Array
containing 35,240 probes at the London Regional Genomics Centre (London, Ontario,
Canada) as described [23]. Three independent cell and RNA isolations were used for each
treatment. Probe data was analyzed, and gene level, ANOVA p-values and fold changes
were determined using Partek Genomics Suite v6.6. Genes with at least 1.5-fold change,
with p<0.05 were considered significant and used for subsequent analyses. The complete
array data set will be publicly available through Gene Expression Omnibus (GEO). The
Venn diagrams were created using the online plotting tool Venny 2.0.1 [24]. KEGG
pathway maps were generated using Ingenuity Pathway Analysis. Gene Ontology
biological processes and cellular component processes were classified through GO
consortium available at geneontology.org using the PANTHER Overrepresentation Test
(released 2016-07-15) and GO Ontology Database (released 2016-10-27), Mus musculus
reference list and Bonferroni correction for multiple testing. Biological processes
identified with more than 3 genes involved were included in the table.

4.3.4

Cellular lipid mass

IMACs were isolated, cultured, and treated with nuclear receptor agonists as described
above. At the 72 hour time point, cells were washed with 0.2% BSA in phosphatebuffered saline (PBS), followed by 3 washes in PBS. Lipids were extracted using 3:2
hexane:isopropanol solvent and pooled. Hexane:isopropanol solvents were evaporated to
dryness under N2 and resuspended in 1.4ml of chloroform-triton (0.5% triton v/v).
Solvent was re-evaporated, and lipids were re-solubilized in 350 µl water. Two 50 µl
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aliquots were used per sample to determine total cholesterol (TC), free cholesterol (FC),
and triglyceride (TG) mass, spectrophotometrically as per [25]. Cholesteryl esters (CE)
were calculated by subtracting FC from TC. Proteins were extracted using 0.2 NaOH
overnight incubation to digest chondrocytes and quantified using a standard BCA protein
assay (Pierce, Thermo Fisher Scientific). All cell lipid measures reported are standardized
to mg of cell protein. Values were normalized relative to vehicle control DMSO, and
statistical analyses were performed using GraphPad Prism 6.0. Values were transformed,
and a one-way analysis of variance (ANOVA) was performed followed by Tukey’s
multiple comparisons tests.

4.3.5

Animals and Surgery

All animal experiments were approved by the Animal Use Subcommittee at The
University of Western Ontario and were conducted in accordance with the guidelines
from the Canadian Council on Animal Care. Mice were group housed (6 mice per cage)
in colony cages, on a standard 12h light/dark cycle with free access to standard mouse
chow, water, and running wheels. Surgical destabilization of the medial meniscus
(DMM) or SHAM surgery was performed on 12 week old C57/bl6 male mice (N=8-9 per
group), as described in [13]. Mice were euthanized at 10 weeks or 12 weeks post-surgery
for preparation of paraffin sections, and subsequent histological analysis. Another cohort
of 20 week old male cartilage-specific Ppard knockout mice and wild-type littermate
controls underwent DMM surgery (N=5 per group) and was harvested for histological
analyses 8 weeks later as in [13]. Ppard mutant mice were bred and genotypes as
described in [13].

Paraffin sections from these studies were employed to evaluate the

presence of Thioredoxin Interacting Protein (Txnip) and Glutathione S-transferase A4
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(Gsta4).

4.3.6

Immunohistochemistry

Immunohistochemistry was performed on frontal sections of paraffin embedded knee
joints as described [26]. Txnip rabbit polyclonal antibody was purchased from
Proteintech (18243-1-AP). Slides without primary antibody were used as controls,
antigen retrieval was performed in 0.1% Triton in H20, and primary antibody was used at
a concentration of 1:300. Gsta4 rabbit polyclonal antibody was purchased from
Proteintech (17271-1-AP) and immunohistochemical staining was performed under the
same conditions as above, except with a primary antibody concentration of 1:100.

4.4
4.4.1

Results
Global changes in chondrocyte gene expression in response to
nuclear receptor agonists

We have previously reported that treatment of articular chondrocytes with the PPARd
agonist GW501516 results in increased catabolic gene expression and robust fatty-acid
oxidation. We have also determined that the LXR agonist GW3965 delays chondrocyte
hypertrophy [13,16]. Identifying which genes are responsible for these phenotypes, and
how they interact with each other, is key to understanding signaling pathways responsible
for joint homeostasis and the prevention of osteoarthritis. We first examined global
changes in chondrocyte gene expression in response to 1µM treatment with LXR agonist
GW3965, RXR agonist SR11237, PPARd agonist GSK501516, or PPARg agonist
Rosiglitazone. RNA was isolated from IMACs cultured with agonists for 72 hours, then
hybridized to Affymetrix microarrays representing the mouse genome.
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We compiled a list of genes changed by more than 1.5 fold (refer to supplementary data
for full list). LXR agonism significantly altered 128 genes (97 upregulated, 31
downregulated), RXR agonism differentially regulated a total of 108 genes (67
upregulated, 41 downregulated), PPARd agonism induced changes in 58 genes (48
upregulated, 10 downregulated), while PPARg agonism changed 32 genes (29
upregulated, 3 downregulated). The most robust and significantly upregulated and
downregulated genes after nuclear receptor agonist treatment are shown in (Figure 4.1).

4.4.2

Nuclear receptors affect common biological functions in
chondrocytes

Comparison of gene expression profiles induced by various nuclear receptor agonists
revealed several common hits. We therefore decided to evaluate shared functional roles
by identifying similar biological processes through Gene Ontology. Supplementary
Table 4.1 indicates the biological processes regulated by agonist treatment for each
nuclear receptor, common processes are highlighted with the same colour. Both LXR and
RXR agonism altered cholesterol biosynthetic processes, while LXR and PPARg
regulated triglyceride metabolism, and RXR and PPARg increased metabolic processes in
chondrocytes. We also investigated GO cellular component processes affected by each
agonist (Supplementary Table 4.2). We noted that the extracellular matrix,
mitochondrion, mitochondrial membrane, and endoplasmic reticulum were key areas in
these processes, and that lipid particles and extracellular space were common between at
least two treatment groups. The identified cellular components were consistent with our
biological processes, heavily implicating the metabolic functions of these nuclear
receptor agonists. In order to compare relationships between nuclear receptor agonist
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treatments, we created a Venn diagram to illustrate the number of genes induced by
multiple receptors [Figure 4.2(a)]. The two genes upregulated by all four nuclear
receptor agonists were Pdk4 and Angptl4. Pdk4 functions as an inhibitor of the pyruvate
dehydrogenase complex. Thus it plays a key regulatory role in shifting energy utilization
from glycolytic to fatty-acid metabolism in the cell [27]. Angptl4 is a well known direct
target of PPARs that is upregulated by hypoxia, and has been characterized as an
adipocytokine [28]. It has also been identified as a potential pro-angiogenic mediator of
arthritis, is involved in ECM remodeling, and is upregulated in the cartilage of RA and
OA patients [29-31]. Larger numbers of genes were regulated by two or three different
agonists [Figure 4.2(a)], and differences in gene regulation between the commonly
induced genes are hierarchically clustered and visually represented in a heatmap [Figure
4.2(b)].
KEGG pathway analysis was subsequently conducted to identify whether the genes
common among agonist treatment would be associated with shared processes. We
discovered that the four agonists shared 13 common pathways (Figure 4.3). Of these, the
most significantly enriched pathways included the PPAR signalling pathway, and the
adipocytokine signaling pathway (Supplementary Figure 4.1 and 4.2). According to our
analyses, all four nuclear receptors are involved in adipocyte differentiation and fatty acid
transport. While LXR, PPARg, RXR regulate lipogenesis, LXR, PPARd, and RXR
mediate fatty acid oxidation and beta oxidation, whereas only PPARd agonism induces
the ketogenic pathway.
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Fig 4.1. Microarray analyses of nuclear receptor agonist effects on chondrocyte gene
expression. Microarray analysis of RNA isolated from immature murine articular
chondrocytes treated for 72 hours with 1µM LXR agonist GW3965 (A), RXR agonist
SR11237 (B), PPARd agonist GSK501516 (C), or PPARg agonist Rosiglitazone (D). The
most highly upregulated and downregulated genes are shown with fold change relative to
vehicle control DMSO (1µM).

132

Figure 4.1 Microarray analyses of nuclear receptor agonist effects on chondrocyte gene
expression
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Fig 4.2. Comparison of nuclear receptor agonist effects on chondrocyte gene
expression (A) Comparison of all genes regulated by the four different nuclear receptor
agonist treatments in chondrocytes demonstrates that 2 genes are commonly regulated by
all four nuclear receptors. Nine genes are commonly regulated by LXR, PPARd, and
RXR, while 4 genes are commonly regulated by LXR, PPARd and PPARg. Three genes
are regulated by LXR, PPARg, and RXR, and 2 genes are commonly regulated by
PPARd, PPARg, and RXR. (B) Differences in regulation of genes changed by at least two
agonists are analyzed through hierarchical clustering and visually displayed in a heatmap.
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Figure 4.2 Comparison of nuclear receptor agonist effects on chondrocyte gene
expression
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Fig. 4.3. Comparison of nuclear receptor agonist effects on affected KEGG
pathways. Comparison of all KEGG pathways enriched by the four different nuclear
receptor agonist treatments in chondrocytes demonstrates that 13 pathways are commonly
enriched by all four nuclear receptors. Seventeen pathways are commonly enriched by
LXR, PPARd, and RXR, while 2 pathways are commonly enriched by LXR, PPARd and
PPARg. Five pathways are commonly enriched by LXR, PPARg, and RXR, and no
pathways are commonly enriched by PPARd, PPARg, and RXR.
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Figure 4.3 Comparison of nuclear receptor agonist effects on affected KEGG pathways
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Since PPARd has opposite effects on OA progression than PPARg and LXR, we were
particularly interested in genes showing opposite responses to the respective agonists.
However, the only gene that was differentially regulated (at our selected threshold)
between any of the treatments was Txnip, which encodes the Thioredoxin interacting
protein. Txnip inhibits Thioredoxin and contributes to ER stress, inflammasome
activation, and the accumulation of reactive oxygen species (ROS) [32]. This gene was
upregulated by PPARd agonist GW501516 and downregulated by LXR agonist GW3965
treatment [Figure 4.2(b)]. Based on the common pathways and genes identified, we next
validated changes in the expression of selected genes by qPCR.

4.4.3

LXR, RXR and PPAR agonism promote changes in genes involved
in ECM homeostasis and chondrocyte metabolism

Genes induced in the microarray were primarily involved in metabolic processes or in
extracellular matrix component production and turnover. We chose to validate a subset of
these genes that were shared between nuclear receptor agonist treatments. Aggrecan and
Fibrillin 2 are extracellular matrix proteins encoded by the Acan and Fbn2 genes. In
concert with our microarray results, gene expression of Acan was significantly lower than
vehicle control (DMSO) with RXR agonist treatment. Similarly, both LXR and RXR
agonism significantly lowered gene expression of Fbn2 (Figure 4.4). Gene expression of
Collagen 2 (Col2a1) remained unchanged in response to any of the treatments. Next we
validated expression of protease genes that were changed by some of the nuclear receptor
agonists, and accordingly found that gene expression of Adamts4, Mmp2 and Mmp13
were significantly reduced by LXR agonism. Interestingly, RXR agonism decreased gene
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Fig. 4.4. Effects of nuclear receptor agonist treatments on extracellular matrix gene
expression in chondrocytes. IMACs were incubated for 72 hours with 1µM DMSO
(vehicle control), PPARd agonist GW501516, PPARg agonist Rosiglitazone, LXR
agonist GW3965, or RXR agonist SR11237. (A) Relative gene expression of Acan gene
is significantly reduced by treatment with the RXR agonist. (B, C) Relative gene
expression of Adamts4 and Fbn2 is significantly reduced by LXR and RXR agonist
treatment. (D, E) Relative gene expression of matrix metalloproteinases Mmp2 and
Mmp13 is decreased by LXR agonist treatment, while gene expression of Mmp13 is
significantly elevated by RXR agonist treatment. (F) Col2a1 gene expression remains
unchanged by all treatments. Values represented are the mean ± SEM of ³ 3 independent
cell isolations. *= p<0.05.
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Figure 4.4 Effects of nuclear receptor agonist treatments on extracellular matrix gene
expression in chondrocytes
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expression of Adamts4 while increasing that of Mmp13 (the primary collagenase of OA),
implying a selective pathway for ECM remodeling and degradation.
LXR, RXR, and PPARs are involved in the regulation of metabolism in a number of
tissues. In a previous study we showed that chondrocytes express functional PPARd and
are capable of responding to GW50516 stimulation with increased fatty acid oxidation
[13]. All four nuclear receptor agonists induced strong effects on genes encoding
metabolic enzymes. Angptl4 and Pdk4, the two common genes induced by all four
nuclear receptors in the microarray, demonstrated a similar robust upregulation in qPCR
validation (Figure 4.5).

Abca1, Cidea, Cpt1a, Lpl, and Insig1 were significantly

increased by PPARd, LXR and RXR agonist treatment, and LXR also significantly
increased the expression of Srebf1. Gene expression of cytoskeletal fatty-acid transporter
Fabp3 was significantly increased by PPARd activation, while Gsta4, a gene encoding an
enzyme for cellular defense against reactive electrophiles [33], was significantly reduced
by both PPARd and RXR agonism.
In a previous study our group has examined the toxicity of the administration of PPARd
agonist GW501516, we have shown that it does not alter cell number [13], while LXR
stimulation increases cell number [16]. Here we examined whether administration of any
of the four nuclear receptor agonists affect cell physiology through changes in gene
expression of markers for proliferation (Ccnd1c, Pcna), cell-cycle exit (p57/Cdkn1c),
apoptosis (Bax), or hypertrophic differentiation (ColX, Runx2) (Supplementary Figure
4.3). We do not see any changes in cell viability, with the exception of RXR agonism
decreasing the expression of Runx2.
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Fig. 4.5. Effects of nuclear receptor agonist treatment on metabolic gene expression
in chondrocytes. IMACs were incubated for 72 hours with 1µM DMSO (vehicle
control), PPARd agonist GW501516, PPARg agonist Rosiglitazone, LXR agonist
GW3965, or RXR agonist SR11237. (A,C,D,G,I) Relative gene expression of Abca1,
Cidea, Cpt1a, Lpl, and Insig1 is significantly increased by PPARd, LXR and RXR
treatments. (B,F) Relative gene expression of Angptl4 and Pdk4 is elevated by all four
treatments. (E) Relative gene expression of Fabp3 is significantly upregulated by PPARd
agonism only. (G) RXR and PPARd treatment significantly decreased relative gene
expression of Gsta4. (H) Srebf1 expression is significantly upregulated by LXR agonism
only. Values represented are the mean ± SEM of ³ 3 independent cell isolations. *p<0.05.
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Figure 4.5 Effects of nuclear receptor agonist treatment on metabolic gene expression in
chondrocytes
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4.4.4

Increased expression of oxidative stress markers in osteoarthritic
cartilage

Txnip plays an important regulatory role in mediating oxidative stress and inflammation
in a number of tissues [32]. Txnip was the only gene differentially regulated between
nuclear receptor agonists. LXR agonist treatment downregulated gene expression, while
PPARd highly induced Txnip. These patterns observed in microarray analyses were
evaluated by qPCR, where PPARd agonism significantly increased gene expression of
Txnip while LXR agonist-treated cells demonstrated trends toward decreased gene
expression, and RXR and PPARg agonism showed no change [Figure 4.6(a)]. To
examine whether Txnip expression is linked to OA, immunohistochemistry for TXNIP
was performed on frontal sections of mice after DMM surgery [Figure 4.6(b,c)]. Wildtype mice 10 weeks post-surgery had increased staining in remaining cartilage compared
to mice that underwent SHAM surgery. To validate the effects of PPARd on Txnip
expression, we compared protein expression in cartilage-specific Ppard KO mice and
wild-type littermates 8 weeks after DMM surgery. Wild-type mice demonstrated
increased staining for Txnip after DMM surgery, particularly in areas of osteophyte
growth at joint margins, whereas both sham-operated control mice and KO mice after
either surgery showed little to no staining. The apparent increase of Txnip expression in
the process of OA implies an imbalance in regulatory processes governing oxidative
stress and inflammation, potentially linking changes in metabolism to osteoarthritic
changes.
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Fig. 4.6. Effects of nuclear receptor agonist treatment and OA on Txnip expression.
(A) IMACs were incubated for 72 hours with 1µM DMSO, PPARd agonist GW501516,
PPARg agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist SR11237. PPARd
treatment significantly increased gene expression of Txnip. Values represented are the
mean ± SEM of ³ 4 independent cell isolations. *p<0.05. (B) IHC for Txnip
demonstrates increased cellular staining in the cartilage of WT DMM mice 10 weeks
post-surgery relative to SHAM mice. (C) IHC for Txnip in cartilage-specific Ppard KO
mice vs WT littermate controls 8 weeks post DMM surgery. Ppard KO mice display less
staining than WT mice after DMM surgery.
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Figure 4.6 Effects of nuclear receptor agonist treatment and OA on Txnip expression
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Fig. 4.7. Effects of nuclear receptor agonist treatment on Gsta4 gene expression. (A)
IMACs were incubated for 72 hours with 1µM DMSO (vehicle control), PPARd agonist
GW501516, PPARg agonist Rosiglitazone, LXR agonist GW3965, or RXR agonist
SR11237. PPARd agonist treatment and RXR agonist treatment both significantly
decreased gene expression of Gsta4. Values represented are the mean ± SEM of ³ 3
independent cell isolations. *p<0.05. (B) Immunohistochemistry for Gsta4 demonstrates
decreased cellular staining in the cartilage of WT DMM mice 12 weeks post-surgery
relative to SHAM mice. (C) Immunohistochemical staining for Gsta4 in cartilagespecific Ppard KO mice vs WT littermate controls 8 weeks post DMM surgery. Both WT
and Ppard KO mice display little to no staining of Gsta4 in the articular cartilage.
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Figure 4.7 Effects of nuclear receptor agonist treatment on Gsta4 gene expression
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In our qPCR validation of target genes, we saw decreased expression of Gsta4 [Figure
4.7(a)] after PPARd and RXR treatment. Gsta4 protects the cell from reactive aldehydes
that are produced as a result of lipid peroxidation or oxidative stress. We assessed the
localization of Gsta4 in the DMM model and found that SHAM operated animals
displayed consistent immunohistochemical staining in superficial cartilage and meniscus,
both in wild type and cartilage-specific Ppard KO mice [Figure 4.7(b,c)]. DMM
operated animals showed little to no staining in cartilage of both genotypes, even if
superficial cartilage remained intact.

4.4.5

Changes in gene expression correspond with functional changes in
chondrocyte lipid profile

In light of the number of genes involved in lipid metabolism that were identified in our
gene expression analyses, we assessed neutral lipid and cholesterol accumulation in
chondrocytes. Using the same nuclear receptor agonist treatment protocols, we harvested
IMACs for cellular lipid mass assays. These assays allowed us to directly quantify
triglycerides and cholesterol in vitro. There were significant changes in cell triglycerides,
but not total cholesterol, free cholesterol or cholesteryl esters (Figure 4.8). These data
suggest that changes in lipid metabolism upon agonist treatment are likely related to
lipogenesis and fatty acid oxidation, rather than cholesterol transport or accumulation. In
particular, triglycerides were significantly decreased with PPARd agonist treatment, and
were significantly elevated with LXR, PPARg and RXR agonism. These changes are
consistent with the known effects of activation of these nuclear receptors on triglyceride
metabolism in other cell types and suggest that PPARd may have an opposing role in
lipid metabolism in chondrocytes relative to the other nuclear receptors examined [34].
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We investigated whether altering metabolic pathways would affect lipid metabolism in
chondrocytes treated with the nuclear receptor agonists. Given that all four agonists
significantly increased the gene expression of PDK4, we performed inhibition of
pyruvate dehydrogenase kinase with a pan- PDK inhibitor (DCA) or PDK4 specific
inhibitor (DADA) (Supplementary Figure 4.4). PDK enzymes act to inhibit pyruvate
dehydrogenase which catalyzes the first step of the pyruvate dehydrogenase complex
(PDC). The PDC oxidizes pyruvate to generate acetyl-coA to be used in the TCA cycled
thereby promoting the preferential oxidation of glucose. Either treatment did not affect
the responses of chondrocyte triglyceride levels to the four agonists.
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Fig. 4.8. Quantification of cellular lipid mass in nuclear receptor agonist-treated
chondrocytes. IMACs were incubated for 72 hours with 1µM DMSO (vehicle control),
PPARd agonist GW501516, PPARg agonist Rosiglitazone, LXR agonist GW3965, or
RXR agonist SR11237. Lipids were extracted, isolated and mass was measured
spectrophotometrically. Proteins were isolated and quantified using BCA. Measurements
are reported relative to mg of cell protein. Absolute mean values for triglycerides, total
cholesterol, free cholesterol and cholesterol esters were 7.4, 27.1, 26.4 and 0.75 ug/mg
protein respectively, for DMSO treated cells. (A) Cell triglycerides (µg) are significantly
elevated by PPARg, LXR, and RXR treatment, and are significantly decreased by PPARd
agonism. (B,C,D) Total cholesterol, free cholesterol, and cholesterol ester remain
unchanged after nuclear receptor agonist treatment. Values represented are the mean ±
SEM of ³ 5 independent cell isolations. *p<0.05.

151

Figure 4.8 Quantification of cellular lipid mass in nuclear receptor agonist-treated
chondrocytes
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4.5

Discussion

This study is among the first to examine changes in global gene expression in
chondrocytes after nuclear receptor agonist treatment, in particular paired with concurrent
functional analysis. It provides compelling evidence that nuclear receptors drive early
changes in cell metabolism that can influence deleterious changes in cellular phenotype
leading to the progression of OA. Nuclear receptors have been increasingly linked to the
progression of OA. We have previously established the degenerative changes promoted
by PPARd agonism in cartilage, as well as the beneficial and necessary role of PPARg in
cartilage [13,14]. We and others have characterized the protective role of LXR in
osteoarthritis [16,35,36]. However, in order to establish how or whether these ligandactivated receptors are feasible therapeutic targets, we must examine the molecular
changes linked to activation or inhibition of each factor.
We used IMACs treated with LXR, RXR, PPARg or PPARd agonists for 72 hours.
Immature murine articular chondrocytes provide a large number of cells for analyses on
fully differentiated primary chondrocytes while minimizing dedifferentiation [19].
Microarray analyses of IMACs revealed changes in metabolic and ECM genes in
response to these agonists, changes which were largely confirmed by qPCR. Agonism of
RXR decreased gene expression of the major ECM component aggrecan, and increased
the expression of ECM protease Mmp13, while LXR agonism decreased the gene
expression of proteases Adamts4, Mmp2, and Mmp13. Of particular interest were the
increases in expression of genes involved in lipid metabolism, since they showed greater
induction than those regulating ECM turnover. Amongst these genes, two were induced
by all four agonists, Pdk4 and Angptl4, suggesting that they might play central roles in
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cartilage metabolism. Interestingly, in an earlier study we had also demonstrated
increased expression of Pdk4 in response to dexamethasone, a ligand for the
glucocorticoid receptor which is another member of the nuclear receptor family [37].
Functional evaluation of lipid metabolism using cellular lipid mass assays demonstrated a
significant decrease in triglycerides after PPARd agonist treatment. Conversely,
triglycerides were significantly increased with PPARg, LXR, and RXR agonists. This is
not surprising as PPARg can often act antagonistically to PPARd with regard to
lipogenesis [38], while LXR mediates fatty acid biosynthesis through activation of genes
such as Srebf1, Fasn, and Scd1 which corroborates our data (see GEO dataset) [39,40].
Quantification of cell lipids in vitro enables us to assess differences in some aspects of
lipid metabolism between treatments. In fact, it is plausible that the dysregulation in lipid
metabolism that we observed could initiate metabolic changes in the cell that eventually
lead to apoptosis, inflammation, or changes in cell behaviour, such as synthesis of
catabolic factors. Increased lipid deposition in osteoarthritic cartilage has been shown,
while increased reactive oxygen species (ROS) can cause lipid peroxidation, which in
turn could cause oxidative stress resulting in degenerative changes to the matrix through
oxidation of collagen II [6]. We also sought to reduce the dysregulation of cell lipids
through the pharmacological inhibition of PDK, which would increase ATP synthesis
through glucose oxidation [41]. However we found that further attempting to shift the
preferred metabolic pathway away from fatty acid oxidation by promoting an alternate
pathway did not change cellular triglyceride levels and agonist responses.
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In addition to dysregulation of cell lipids, we also see significantly decreased Gsta4
expression after PPARd or RXR agonist treatment. The encoded enzyme Glutathione Stransferase A 4 protects against HNE (4 Hydroxynonal)-induced damage in
chondrocytes. HNE is an extremely reactive aldehyde produced from ROS and lipid
peroxidation, and is increased in synovial fluid from OA patients [40] as well as articular
cartilage [42]. HNE can also post-transcriptionally modify Collagen 2 and MMP13 to
induce degradative changes in cartilage as well as changes in cell-matrix interactions
[43,44]. Molecularly, it has been observed that HNE can stimulate COX-2 via the
ATF/cAMP response element and inhibits iNOS and NF-kB inactivation in human
articular chondrocytes [45]. GSTs are major determinants of intracellular HNE
concentration, and dysregulation in disease states can result in toxic effects [46]. The
GSTA4 isoform has well established selectivity and efficiency for conjugation of lipid
peroxidation products, especially HNE [46,47]. Accordingly, decreased levels of GSTA4
are present in human OA cartilage, making cartilage more susceptible to damage [33]. In
addition, IL-1b treatment of human articular chondrocytes decreases expression of Gsta4,
while inhibition of the p38 MAPK pathway (an important signaling pathway in the
pathogenesis of OA) increases levels of Gsta4 [48]. This suggests that the catabolic
effects of PPARd (and possibly RXR) in cartilage could be partially due to decreased
expression of Gsta4, resulting in decreased anti-oxidant defense and thus increased
oxidative stress. In our surgical model of DMM induction, we see that even the minimal
damage experienced by PPARd KO after surgery is enough to decrease the expression of
this protein in-vivo, indicating that Gsta4 is an early response gene to damage and that
there may be multiple pathways that influence its regulation.
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Another gene of interest, Txnip (thioredoxin interacting protein), was highly induced by
PPARd agonism, but appeared repressed by LXR agonism, in agreement with the
opposing effects of these nuclear receptors on OA progression. Thioredoxin is another
important antioxidant, but binding of Txnip to thioredoxin inhibits its ability to scavenge
for ROS [49]. In humans, decreased TXNIP is seen at late stages of OA, while increased
TXNIP is seen in H2O2 induced cartilage damage in human chondrocytes [50,51]. In our
study, we demonstrate increased gene expression of Txnip after PPARd agonism in
chondrocytes, and control mice show increased staining for Txnip after DMM surgery.
The apparent differences in Txnip regulation in human and mouse OA are likely due to
the different disease stages; human data were obtained from end stage samples, while the
DMM model is subtle and our analyses has largely focused on mild to moderate disease.
We also show that cartilage-specific Ppard knockout mice that are protected against
cartilage degeneration in the DMM model have decreased Txnip staining after DMM
surgery, in line with our microarray data. Txnip has been linked to oxidative stress and
inflammation, and it can directly activate NF-kB and downstream inflammatory
cytokines [52]. In chondrocytes, recent work has shown that Redd1 can form a complex
with Txnip to regulate autophagy [53]. Taken altogether, these data help to form a
cohesive picture of how changes in cell metabolism could influence the development of
early osteoarthritis. Nuclear receptors appear to play a key role in these processes by
regulating the expression of central players such as Txnip and Gsta4.
Current treatment strategies for OA are largely ineffective or inconclusive. It is possible
that we are missing a critical temporal period during which chondrocyte homeostasis is
disrupted, later leading to matrix degeneration. Recent evidence demonstrates that
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nuclear receptors are key regulators of OA pathogenesis, and the data presented here
suggests that their primary targets are metabolic regulation. Metabolic deregulation, in
turn, can trigger events leading to oxidative stress and inflammation, protease activation,
and ultimately cartilage degeneration. Targeting these critical processes could be a
promising avenue for treatments that alter disease progression.
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4.7

Supplementary Tables

Supplementary Table 4.1: Biological processes differentially regulated by nuclear
receptor agonists as indicated by Gene Ontology (GO) bioinformatics analysis.
Commonly regulated biological processes between treatments are indicated by the same
color.
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Supplementary Table 4.2. Cellular components differentially regulated by nuclear
receptor agonists as indicated by Gene Ontology bioinformatics analysis. Commonly
regulated cellular components between treatments are indicated by the same color.

159

Supplementary Table 4.3. KEGG pathways commonly affected by all 4 nuclear
receptor agonist treatments with corresponding enrichment p-values. Extensive pathway
maps are provided in subsequent supplementary figures for pathways marked with
asterisks (*).

160

4.8

Supplementary Figures

Supplementary Figure 4.1. Pathway mapping of PPAR signaling. The PPAR
signaling pathway is significantly enriched by all four nuclear receptor agonist
treatments. Differentially expressed genes as a resulted of each nuclear receptor agonism
is mapped onto the PPAR signaling pathway, with gene expression fold-changes ranging
from -2 to +2 represented by a color gradient of red or green, respectively.
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Supplementary Figure 4.2. Pathway mapping of adipocytokine signaling. The
adipocytokine signaling pathway is significantly enriched in all four nuclear receptor
agonist treatments. Differentially expressed genes as a result of each nuclear receptor
agonism is mapped onto the adipocytokine pathway, with gene expression fold-changes
ranging from -2 to +2 represented by a color gradient of red or green, respectively.
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Supplementary Figure 4.3. Effects of nuclear receptor agonist treatment on
chondrocyte viability and differentiation gene expression. IMACs were incubated for
72 hours with 1µM DMSO (vehicle control), as well as the respective agonists of
PPARd, PPARg, LXR or RXR. (A, B, C, D, F) Relative gene expression of cell viability
markers Pcna, Cdkn1c, Ccnd1, and Bax, as well as chondrocyte maturation marker
Col10a1 are not significantly changed with all four nuclear receptor activation. (E)
Relative gene expression of terminal chondrocyte differentiation marker Runx2 is
significantly decreased with RXR activation but not by any of the other three nuclear
receptor agonists. Values represented are the mean ± SEM of ³ 3 independent cell
isolations. *= p<0.05.
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Supplementary Figure 4.4. Quantification of cellular lipid mass in nuclear receptor
activated IMACs treated with Pdk-inhibitors. IMACs were incubated for 72 hours
with 1µM DMSO (vehicle control), PPARd agonist GW501516, PPARg agonist
Rosiglitazone, LXR agonist GW3965, or RXR agonist SR11237, together with water
(vehicle), DCA or DADA. Lipids were extracted, isolated and mass was measured
spectrophotometrically. Proteins were isolated and quantified using BCA. Measurements
are reported relative to mg of cell protein. (A) Cell triglycerides (µg) are not significantly
altered by dichloroacetic acid (DCA) treatment in PPARg, PPARd, LXR, or RXR agonist
treated chondrocytes. (B) Levels of cell triglycerides also remain unchanged with
diisopropylamine dichloroacetate (DADA) treatment in PPARg, PPARd, LXR, or RXR
agonist treated chondrocytes. Values represented are the mean ± SEM of ³ 5 independent
cell isolations. *p<0.05.
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Chapter 5

5

Discussion

5.1

Overview

The overall objective of this thesis was to elucidate the roles of Liver X Receptor (LXR)
and Retinoid X Receptor (RXR) in chondrocyte biology and cartilage health.
Specifically, I was interested in examining the roles of these nuclear receptors in
transcriptional regulation of intracellular signalling pathways in both cartilage
development and homeostasis, and thus directed my studies in the context of
endochondral bone formation and osteoarthritis (OA). Nuclear receptors have long been
investigated for their orchestration of a plethora of developmental and physiological
processes [1], however their implications in cartilage biology are less well known. In
recent years, our laboratory has focused on investigating lipid-derived ligand activated
nuclear receptors, and has found several to play key functions in chondrocyte
differentiation and osteoarthritis [2-4]. We first identified the RAR-related orphan
receptor-a (RORa) as a novel regulator of in vitro chondrocyte hypertrophy activated by
cholesterol signalling [3]. Around this time several studies detailing potential therapeutic
mechanisms of LXR in OA were conducted, where LXRb-deficient mice experienced
increased proteoglycan degradation in the articular cartilage compared to wild-type
littermates [5]. LXRa and LXRb expression was further found to be decreased in human
OA articular cartilage, and synthetic LXR agonist administration was able to restore
LXR-activated transcription in human OA articular cartilage explants [5, 6]. However,
the cellular and molecular mechanisms behind this protective effect remained
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unexplored. Since LXR has long been known as a cholesterol-responsive nuclear receptor
that regulates intracellular cholesterol homeostasis, this provided the rationale for
investigating its roles in chondrocyte hypertrophy and its relations to OA.
The first study of my thesis aimed to do exactly that, and I investigated the role of LXR
in endochondral ossification by pharmacologically activating LXR using a specific
agonist, GW3965. I utilized several well established chondrogenic cultures to carefully
study LXR function in each stage of chondrocyte differentiation, including ATDC5 cell
cultures, micromass cultures, and ex vivo tibiae organ cultures [7-12]. I discovered that
LXR activation caused a delay in chondrocyte hypertrophy in all three chondrogenic
culture systems. Specifically, GW3965 treatment not only significantly decreased the
length of the hypertrophic zone in tibia organ cultures, but it also resulted in marked
decrease of chondrocyte hypertrophy markers alkaline phosphatase, Col10a1, Mmp13,
Ihh, and Runx2. Interestingly, MTT assay and cell-counting also showed LXR activation
to result in increased chondrocyte number and viability, and immunohistochemical
analysis of the cyclin-dependent protein kinase inhibitor, p57, showed decreased positive
staining upon LXR agonism. Taken together, these findings suggest LXR activation to
suppress chondrocyte hypertrophy, in part through the delay of cell-cycle exit and
retention of these chondrocytes in the proliferative phase. I therefore concluded
suppression of chondrocyte hypertrophy by LXR to be an underlying mechanism of its
protective roles against OA.
Given our findings, it was imperative that we next identify putative LXR target genes in
chondrocytes in order to better understand the intracellular changes that occur to elicit
this cellular phenotypic change. As LXR is a transcription factor directly regulated by
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endogenous and synthetic ligands [13], we conducted microarray analysis on primary
growth plate chondrocytes treated with the LXR-specific agonist GW3965 for a period of
24 hours, in order to examine genome-wide changes in gene expression. Interestingly,
LXR activation caused differential regulation of various genes involved in lipid
metabolism. Among these, several key mediators of cellular cholesterol efflux, Abcg1
and Abca1, as well as an important transcriptional regulator of lipid biosynthesis, Srebp1,
were up-regulated. Immunohistochemical analysis of LXR as well as these
aforementioned targets were all shown to be preferentially localized to the prehypertrophic and resting zones of the growth plate, suggesting similar regulatory
mechanisms. It is possible that Srebp1’s activation of Scd1 (which was also up-regulated
from our microarray) contributes to LXR’s roles in maintaining cholesterol homeostasis
by increasing production of fatty acids necessary for cholesterol esterification [14]. This
creates a cholesterol sensor employed by LXR to prevent cholesterol overload, which
appears to also be at play in articular chondrocytes upon comparison of expression
profiles. Collectively, these findings demonstrate LXR activation in growth plate
chondrocytes to result in transcriptional activation of various lipid homeostatic functions,
especially those involved in cholesterol efflux.
It has been well documented that ectopic initiation of chondrocyte hypertrophy can occur
in the articular cartilage to contribute to OA onset [15-17]. However, it remains unclear
which specific mechanisms actually cause these articular chondrocytes to undergo
hypertrophy. To gain insight into LXR’s regulation of transcriptional activity in articular
chondrocytes, we conducted microarray analysis on immature murine articular
chondrocytes (IMACs) treated with the LXR agonist GW3965. Since both LXR isoforms
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form permissive obligate heterodimers with another nuclear receptor, RXR, we
performed additional microarray studies examining the effects of RXR activation, as well
as activation of two other RXR heterodimeric partners – peroxisome proliferatoractivated receptors-g and -d (PPARg and PPARd, which will not be discussed here as
they form part of a different project). Both LXR and RXR activation resulted in
differential expression of genes involved in cholesterol biosynthesis and fatty acid
oxidation. Functional validation of cellular lipid mass revealed both LXR and RXR to
significantly increase cellular triglyceride levels. Although LXR activation also incurred
a decreasing trend in free cholesterol, cholesterol ester, and total cholesterol levels, these
decreases were not significant. Furthermore, LXR and RXR activation were found to
exert opposite effects on Mmp13 expression, the primary collagenase of OA, suggesting
contrary roles in OA pathogenesis.

Lastly, examination of differentially regulated

oxidative stress markers revealed LXR agonism to increase Txnip expression while RXR
agonism decreased Gsta4 expression. While Gsta4 plays a protective effect in response to
oxidative stress [18], Txnip can aggravate its effects [19, 20], suggesting LXR and RXR
agonism to play contrasting roles in oxidative stress and resulting OA progression. These
findings lead to the conclusion that while these nuclear receptors cause global changes in
gene expression in IMACs, they exert opposing regulatory effects on genes involved in
ECM homeostasis and oxidative stress.
In summary, these studies come together to demonstrate that LXR and RXR regulate
numerous cellular mechanisms involved in metabolic homeostasis of both growth plate
and articular chondrocytes. The ECM changes induced as a result of nuclear receptor
agonism is likely secondary to these changes in cellular metabolism. These findings
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ultimately help achieve better understanding of the molecular pathways involved in
chondrocyte behavior in both healthy and diseased states.

5.2
5.2.1

Contributions and Significance of Findings
Contributions to the field of cartilage biology

Although a number of studies have been conducted investigating nuclear receptor
function in endochondral bone growth, much less is known regarding the function of
lipid-derived ligand activated nuclear receptors such as LXR, RXR, and the PPARs. This
is in part due to the relatively limited understanding of lipid homeostasis in cartilage
health, and how alterations of this can potentially contribute to disease. It is known that
cholesterol not only acts as signaling molecules but is also essential for maintaining the
structural integrity of the cellular membrane [21]. Proper maintenance of optimal
cholesterol levels is crucial for cartilage health where studies have shown cholesterol
deficiency to detrimentally affect bone growth leading to skeletal dysplasia [22, 23],
while a previous study from our lab has shown exogenous cholesterol treatment of tibia
organ cultures to result in increased bone growth and much larger and rounder growth
plate chondrocytes [3]. Our findings from our microarrays add a piece to this puzzle by
suggesting LXR to be a central regulator maintaining cholesterol balance by
transcriptionally activating various lipid metabolic markers. In particular, although LXR
has been extensively implicated in reverse cholesterol transport and cholesterol efflux of
peripheral tissues [24], we show for the first time the same markers to be upregulated in
both growth plate and articular chondrocytes. We also are among the first to then
functionally validate alteration of cellular lipid content of articular chondrocytes by
nuclear receptor agonism, further validating their regulatory roles in lipid metabolism in
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this tissue. Our final study additionally examined nuclear receptor function in articular
chondrocytes, and further identified several genes involved in cellular oxidative stress
and remodelling of the ECM to be changed, suggesting LXR and RXR activation to also
play a role in regulating these cellular and extracellular processes in cartilage.

5.2.2

Contributions to the field of osteoarthritis

In this thesis, we characterize several novel roles of LXR and to a lesser extent, RXR, in
the current understanding of OA pathophysiology. As previously discussed, at the time of
initiating our first study, several studies have been conducted by others demonstrating
evidence for therapeutic potential of LXR activation in OA [5, 6]. However, the
underlying mechanism behind this protective effect remained unknown. By activating
LXR in ex vivo tibia organ cultures as well as various in vitro models of chondrogenic
differentiation, we were able to show LXR activation to suppress chondrocyte
hypertrophy at both the transcriptional and protein level. While it still remains unclear
whether it is the cellular change into hypertrophy or simply the induction of hypertrophyrelated markers that contributes to OA-related changes in the cartilage [25], several lines
of evidence suggest the latter to be more likely. For example, although mice deficient for
Mmp13 experience protection from cartilage degeneration, chondrocyte hypertrophy is
still present [26]. Extensive evidence also exists showing LXRa to regulate
cardiomyocyte hypertrophy, where both agonist administration and cardiac-specific
overexpression of LXRa were shown to attenuate cardiomyocyte hypertrophy [27–29].
Taken together, modulation of LXR appears to possess strong therapeutic potential to
target attenuation of the harmful effects of cellular hypertrophy under various diseased
states.
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Dysregulation of lipid homeostasis within the body has long been associated with OA
pathogenesis. Metabolic complications such as those categorized in metabolic syndrome,
as well as increased levels of circulating adipokines and lipids, have both been implicated
in OA progression [30-33]. At the tissue level, excessive cholesterol and fatty acids have
been shown to accumulate in the superficial areas of human osteoarthritic cartilage [34],
although not much is known regarding the mechanisms behind this accumulation.
Findings from my third and fourth chapters suggest LXR to play a regulatory role in this
accumulation in chondrocytes by transcriptionally activating genes involved in
cholesterol efflux. This is in line with a recent study that aimed to characterize the effects
of hypercholesterolemia on OA progression through the use of apolipoprotein E-deficient
mice (ApoE-/-). Specifically, ApoE-/- mice fed a high cholesterol diet experienced more
severe OA symptoms upon surgical induction of OA compared to mice on the control
diet [35]. Interestingly, this was accompanied by increased expression of chondrocyte
hypertrophy markers and overproduction of reactive oxygen species (ROS),
demonstrating a link between hypercholesterolemia and chondrocyte phenotype, altered
mitochondrial function, and oxidative stress. Our findings demonstrating LXR’s
activation of the cholesterol efflux membrane transporters Abca1 and Abcg1, as well as
the LXR-Srebp1-Scd1 axis, solidify LXR’s regulation on cholesterol efflux within
chondrocytes, although further studies are needed to examine this process during
pathological states of OA.
Indeed, our microarray analysis conducted on IMACs treated with nuclear receptor
agonists show LXR activation to increase expression of Txnip, and RXR activation to
decrease expression of Gsta4. Txnip encodes for thioredoxin-interacting protein that
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negatively regulate thioredoxin’s ability to reduce oxidative stress [19, 20], whereas
Gsta4 encodes for the enzyme glutathione S-transferase A-4 that protects against the
harmful effects of lipid peroxidation product 4-hydroxynonenal (HNE) [18]. HNE has
been shown to be largely responsible for the oxidative stress of lipid peroxidation, and
can contribute to degradation of ECM components such as collagen II by inducing
Mmp13 release [36, 37]. Our findings demonstrate LXR and RXR activation to result in
contrasting effects on genes involved in ECM homeostasis, where Mmp13 expression
was significantly induced by RXR agonism but reduced by LXR agonism. It is possible
that the contrasting regulation of oxidative stress markers by LXR and RXR contributes
to their opposing effects on ECM homeostasis markers, and it is possible that this stems
from potential differences in altering lipid homeostasis within chondrocytes. As RXR
acts as the obligate heterodimeric partner to a number of other nuclear receptors, its
modulation of multiple metabolic pathways may account for this difference [38].
Nevertheless, further elucidation of RXR’s role in regulating lipid metabolism in
cartilage under healthy and diseased states is needed for further conclusive insights on its
role within this context.

5.3
5.3.1

Limitations of Research
Limitations of in vitro models

For any experimental study, it is important to recognize and acknowledge existing
limitations in order to properly interpret results and evaluate its significance. Perhaps one
of the greatest shortcomings of this thesis lies in the lack of in vivo validation of our
findings. In vitro cell culture systems often fail to recapitulate the true physiological
environment within the body, and in the case of both growth plate and articular
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chondrocytes, the complex signalling between different types of tissues that make up the
long bone and the synovial joint are all essential for proper development and maintenance
of health [39, 40]. Likewise, in vitro cultures of primary chondrocytes are often in the
form of a monolayer, and do not reflect the 3-dimensional architecture of cartilage nor
the abundance of extracellular matrix. This disparity is even larger in the articular
cartilage, where the low cellular volume density and variable oxygen tension and nutrient
supply can be hard to emulate. Nevertheless, in vitro cell culture systems are absolutely
necessary for elucidating underlying mechanisms behind physiological effects. This is
especially true when studying chondrocyte differentiation within the growth plate, since
chondrogenic cultures such as ATDC5 cells and micromass cultures allow for careful
analysis of each stage of differentiation throughout the entire process. Our
acknowledgement of potential weaknesses of in vitro systems is the reason behind our
utilization of different chondrogenic cultures (monolayer cultures, micromass cultures,
organ cultures) that capture both the physiological environment of isolated cells and of
entire organs.
Furthermore, the extremely well-controlled in vitro setting can elucidate pharmacological
effects in the absence of confounding systemic effects, and are therefore invaluable for
the study of nuclear receptors and other factors whose activity are modulated by
exogenous ligands. In the case of nuclear receptor activation, our study could have
benefited from examining microarray targets under several different agonist
concentrations to see if higher concentrations could result in greater induction of target
genes. In addition, microarray analysis was conducted on primary growth plate
chondrocytes after only 24 hours of agonist treatment, whereas for IMACs it was
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conducted after 72 hours of treatment. A longer treatment period could lead to expression
changes in genes secondary to the initial effect of transcriptional regulation, and result in
the identification of genes that are likely not direct targets of these nuclear receptors.

5.3.2

Limitations of genome-wide expression analyses

A large subset of our studies relied on microarray analysis for transcriptome profiling of
nuclear receptor activation in chondrocytes. However, microarrays are no longer the
optimal technique for elucidating genome-wide expression changes due to its potential
detection bias of individual probes [41]. RNA-sequencing can be used to provide a
comprehensive and unbiased approach at detecting all RNA species, including miRNAs
and other non-coding RNAs [41]. Nevertheless, next-generation sequencing such as RNA
sequencing still lack the ability to identify direct target genes. As such, techniques such
as chromatin immunoprecipitation sequencing (ChIP-Seq) needs to be performed and its
results directly compared to RNA-sequencing data in order to identify interactive sites
between the nuclear receptor of interest and genomic DNA at or near genes that display
changes in expression. However, the success of ChIP experiments is largely dependent on
1) protein binding affinity to DNA; 2) the quality of the primary antibody; and 3) the
expression of the protein of interest in tissue sample. As certain nuclear receptors can
demonstrate lower expression in less metabolically active tissues, primary antibodies of
exceptional quality are needed but remains scarce at this present moment.
Bioinformatics analyses of global gene-expression datasets are another source of
potential bias. In order to make sense of a large dataset, genes are often annotated and
then classified into functional categories using established tools such as Gene Ontology
(GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. While these
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functional categories allow for a good overview of biological processes involved in
various experimental conditions, selecting which GO terms or KEGG pathways to
present is often subject to the author. Even when categorized hierarchically using
enrichment values, it is important to note that while a higher enrichment score may mean
higher representation of your gene set in a particular functional category, this
representation may be skewed since the number of genes in each category often vary. It is
also worth noting that potential biological biases can exist as a result of the highly
specialized nature of each specific cell type [42]. In this case, the reported functional
categories of a cell type may simply reflect the biological bias a specific tissue has for
specific pathways, and potentially miss genes that experienced large expression changes
but are not part of a conventional metabolic processes expected by the tissue. Ultimately,
all of these potential biases were taken into consideration during the analysis of our
microarray data in order to provide the most accurate overview of the results. It is also
without doubt that despite these potential limitations, microarray analysis continues to be
used as a quick and relatively cost-effective method to examine changes in transcriptome
profiles on the broader scale.

5.4

Future Directions

The studies conducted in this thesis has provided several avenues in which further studies
can be conducted to provide insight into the workings of nuclear receptor function in
cartilage biology. In the case of solidifying LXR’s role in activating cholesterol efflux as
a proposed mechanism of suppressing chondrocyte hypertrophy, it will be interesting to
examine the effects of LXR activation on chondrocyte hypertrophy under conditions of
high cholesterol, as it is expected that the pathological manifestations of hypertrophy
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could be attenuated under agonist administration. Additionally, it still remains unclear as
to why positive immunohistochemical staining of LXR (as well as several identified
microarray targets) within the growth plate changes from wide-spread distribution to
preferential localization to the pre-hypertrophic and resting zones when treated with
GW3965. As such, examining the effect of LXR agonism on LXR gene expression
throughout the process of chondrocyte differentiation will elucidate potential
autoregulatory mechanisms exerted by LXR, as well as provide further understanding
into the relation between LXR activation and changes in chondrocyte phenotype.
As previously mentioned, due to the obvious limitations of in vitro cell culture
techniques, it is of great interest to us that we validate our findings in in vivo animal
models. In particular, murine models of surgically induced OA or hypercholesterolemia
could be utilized to examine the effect of pharmacological activation of LXR and/or RXR
under diseased states. As these nuclear receptors are master regulators of metabolic
homeostasis, their true function can be better elucidated under conditions of physiological
stress. Similarly, conditional knockout animal models can be used to examine the effect
of LXR and/or RXR deficiency specifically in the developing or articular cartilage
through the utilization of tissue-specific Cre drivers, including Col2a1-Cre and Agc1CreER(T2) [2, 43, 44]. This will allow us to examine the role of LXR and/or RXR in
both skeletal development and cartilage degeneration throughout the lifespan. Disease
models can be used with these animals to complement the previously proposed study to
better characterize their roles. Several of these studies are currently underway in our
laboratory and are expected to show interesting results. As LXR has been found to
possess species-specific effects by differentially regulating target genes to result in
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differences in lipid and immune profiles between rodents and humans [45–48], it is
important that significant findings are ultimately validated in humans in order to account
for these differences.
The fourth chapter of this thesis identified several key regulators of oxidative stress that
warrants further investigation. In particular, Txnip has recently been identified to work
with Redd1 to regulate autophagy in aging chondrocytes [49]. As autophagy is known to
be altered in OA pathogenesis and plays a role in protecting cells from conditions of
oxidative stress [50, 51], further examination of the effect of nuclear receptor activation
on autophagy can provide better insight into this protective mechanism. Additionally,
while the role PPARd plays in regulating Txnip and Gsta4 has been functionally
validated in surgically-induced OA, the same remains to be done with LXR and RXR.
These studies will act to confirm their role in regulating these oxidative stress markers in
articular chondrocytes, further solidifying their therapeutic potential in the context of
osteoarthritis.
In conclusion, collectively our studies show pharmacological activation of LXR, and to a
lesser extent RXR, to regulate lipid homeostasis within growth plate and articular
chondrocytes. In the case of LXR, this regulatory mechanism may contribute to its
protective role against cartilage degradation in OA, in part through its suppression of
chondrocyte hypertrophy and involvement in cellular response to oxidative stress.
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Appendices
Appendix A: Animal Use Protocol

2015-031:2:

AUP Number: 2015-031
AUP Title: Regulation of Endochondral Bone Growth by Hormones
Yearly Renewal Date: 07/01/2017

The YEARLY RENEWAL to Animal Use Protocol (AUP) 2015-031 has been
approved by the Animal Care Committee (ACC),
and will be approved for one year following the above review date.

Please at this time review your AUP with your research team to ensure full
understanding by everyone listed within this AUP.

As per your declaration within this approved AUP, you are obligated to ensure that:

1) Animals used in this research project will be cared for in alignment with:
a) Western's Senate MAPPs 7.12, 7.10, and 7.15
http://www.uwo.ca/univsec/policies_procedures/research.
html
b) University Council on Animal Care Policies and related
Animal Care Committee procedures
http://uwo.ca/research/services/animalethics/animal_car
e_and_use_policies.html
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2) As per UCAC's Animal Use Protocols Policy,
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including
permits and scientific/departmental peer approvals, are complete and accurate;
c) any divergence from this AUP will not be undertaken
until the related Protocol Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and
Full AUP Renewals - will be submitted
ACC.

and attended to within timeframes outlined by the
http://uwo.ca/research/services/animalethics/animal_use_protocols.html

3) As per MAPP 7.10 all individuals listed within this AUP as having any
hands-on animal contact will
a) be made familiar with and have direct access to this
AUP;
b) complete all required CCAC mandatory training; and
c) be overseen by me to ensure appropriate care and use
of animals.
4) As per MAPP 7.15,
a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to
ACVS Veterinarians and ACC Leaders;
c) UCAC policies and related ACC procedures will be
followed, including but not limited to:
i) Research Animal Procurement
ii) Animal Care and Use Records
iii) Sick Animal Response
iv) Continuing Care Visits
5) As per institutional OH&S policies, all individuals listed within this AUP
who will be using or potentially
exposed to hazardous materials will have completed in advance the
appropriate institutional OH&S training, facility-level training, and reviewed related
(M)SDS Sheets, http://www.uwo.ca/hr/learning/required/index.html
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Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care

Dr.Timothy Regnault,
Animal Care Committee Chair

The University of Western Ontario
Animal Care Committee / University Council on Animal
Care
London, Ontario Canada N6A 5C1

http://www.uwo.ca/research/services/animalethics/index.html
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